Your activity: 2 p.v.

Fluoxetine: Drug information

Fluoxetine: Drug information
(For additional information see "Fluoxetine: Patient drug information" and see "Fluoxetine: Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
ALERT: US Boxed Warning
Suicidality and antidepressant drugs:

Antidepressants increased the risk compared with placebo of suicidal thinking and behavior (suicidality) in short-term studies in children, adolescents, and young adults with major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of fluoxetine or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared with placebo in adults older than 24 years; there was a reduction in risk with antidepressants compared with placebo in adults 65 years and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Appropriately monitor and closely observe patients of all ages who are started on antidepressant therapy for clinical worsening, suicidality, or unusual changes in behavior. Advise families and caregivers of the need for close observation and communication with the prescribing health care provider.

Fluoxetine is approved for use in children with MDD (aged 8 years and older) and obsessive-compulsive disorder (OCD; aged 7 years and older). Sarafem is not approved for use in children.

Brand Names: US
  • PROzac;
  • Sarafem [DSC]
Brand Names: Canada
  • ACH-FLUoxetine;
  • ACT FLUoxetine [DSC];
  • AG-Fluoxetine;
  • APO-FLUoxetine;
  • Auro-FLUoxetine;
  • BIO-FLUoxetine;
  • DOM-FLUoxetine;
  • JAMP-FLUoxetine;
  • MINT-FLUoxetine;
  • NRA-Fluoxetine;
  • Odan-FLUoxetine;
  • PMS-FLUoxetine;
  • PRIVA-FLUoxetine [DSC];
  • PRO-FLUoxetine;
  • PROzac;
  • RIVA-FLUoxetine;
  • SANDOZ FLUoxetine [DSC];
  • TEVA-FLUoxetine;
  • VAN-FLUoxetine [DSC]
Pharmacologic Category
  • Antidepressant, Selective Serotonin Reuptake Inhibitor
Dosing: Adult

Note: In patients sensitive to adverse effects, some experts suggest lower starting doses of 5 to 10 mg/day and gradual titration in increments of no more than 10 mg, particularly in patients with anxiety who are generally more sensitive to overstimulation effects (eg, anxiety, insomnia) with antidepressants (Ref).

Binge eating disorder

Binge eating disorder (off-label use): Limited data available: Oral: Initial: 10 to 20 mg once daily; may increase dose based on response and tolerability in increments of 10 to 20 mg at intervals ≥1 week up to 80 mg/day (Ref).

Bipolar major depression

Bipolar major depression: Oral: Initial: 20 mg once daily in the evening in combination with olanzapine (preferred), another second-generation antipsychotic, or antimanic agent; may increase dose in 10 to 20 mg increments every 1 to 7 days (Ref); usual dose range: 20 to 50 mg/day (Ref). May also use the fixed-dose combination instead of the separate components. See Dosing conversion below for conversion to or from olanzapine/fluoxetine fixed-dose combination.

Body dysmorphic disorder

Body dysmorphic disorder (BDD) (off-label use): Oral: Initial: 20 mg once daily; may increase dose gradually based on response and tolerability in increments of 20 mg every 2 to 3 weeks to a usual dose of 70 to 80 mg/day by week 6 to 10 (Ref). Doses up to 120 mg/day, if tolerated, may be necessary in some patients for optimal response (Ref). Note: An adequate trial for assessment of effect in BDD is 12 to 16 weeks, including maximum tolerated doses for at least 3 to 4 of those weeks (Ref).

Bulimia nervosa

Bulimia nervosa: Oral: Initial: 20 mg once daily; may increase dose gradually (eg, at intervals ≥1 week) based on response and tolerability in 20 mg increments up to a target dose of 60 mg/day (Ref).

Manufacturer's labeling: Dosing in prescribing information may not reflect current clinical practice. Initial: 60 mg/day

Fibromyalgia, refractory

Fibromyalgia, refractory (alternative agent) (off-label use): Note: For patients not responsive to first-line agents (Ref). Oral: Initial: 20 mg once daily; may increase dose based on response and tolerability in 10 to 20 mg increments at ≥2-week intervals up to 80 mg/day. Mean dose in clinical trials was 45 mg/day (Ref). In patients with an insufficient response to first-line monotherapy, some experts suggest low-dose combination therapy (eg, fluoxetine 20 mg/day with a tricyclic antidepressant) (Ref).

Generalized anxiety disorder

Generalized anxiety disorder (off-label use): Limited data available: Oral: Initial: 10 to 20 mg once daily; may gradually increase dose based on response and tolerability in 10 to 20 mg increments at intervals of ≥1 week up to 60 mg/day (Ref).

Major depressive disorder

Major depressive disorder (unipolar): Oral: Initial: 20 mg once daily; may increase dose based on response and tolerability in 20 mg increments at intervals ≥1 week up to a maximum dose of 80 mg/day (Ref). Usual dose: 20 to 60 mg/day (Ref). Note: For treatment-resistant depression, combination with olanzapine or another second-generation antipsychotic may be used; in major depression with psychotic features, fluoxetine plus an antipsychotic is standard treatment (Ref). May consider use of the fixed-dose combination instead of the separate components. See Dosing conversions below for conversion to or from the olanzapine/fluoxetine fixed-dose combination.

Obsessive-compulsive disorder

Obsessive-compulsive disorder: Oral: Initial: 10 to 20 mg once daily; may increase dose gradually in 20 mg increments at intervals ≥1 week based on response and tolerability; recommended range: 40 to 80 mg/day (Ref). Based on clinical experience, some patients may require up to 120 mg/day for a response; however, adverse effects may increase (Ref). Note: An adequate trial for assessment of effect in OCD is considered to be ≥6 weeks at maximum tolerated dose (Ref).

Panic disorder

Panic disorder: Oral: Initial: 5 to 10 mg once daily; after 3 to 7 days, gradually increase dose based on response and tolerability in 5 to 10 mg increments at intervals ≥1 week up to a usual dose of 20 to 40 mg/day (Ref). Maximum dose: 60 mg/day (Ref).

Posttraumatic stress disorder

Posttraumatic stress disorder (PTSD) (off-label use): Oral: Initial: 10 to 20 mg once daily; may increase dose based on response and tolerability in 10 to 20 mg increments at intervals ≥1 week up to 80 mg/day. Usual dosage range in clinical trials: 20 to 60 mg/day (Ref).

Premature ejaculation

Premature ejaculation (off-label use): Limited data available: Oral: Initial: 20 mg once daily; may increase dose based on response and tolerability after ≥1 week (some experts suggest 3- to 4-week titration intervals (Ref)) to 40 mg once daily (Ref).

Premenstrual dysphoric disorder

Premenstrual dysphoric disorder (PMDD):

Continuous daily dosing regimen: Oral: Initial: 10 mg once daily; increase to usual effective dose of 20 mg once daily over the first month; in a subsequent menstrual cycle, a further increase to 30 mg/day may be necessary in some patients for optimal response (Ref).

Intermittent regimens:

Luteal phase dosing regimen: Oral: Initial: 10 mg once daily during the luteal phase of menstrual cycle only (ie, beginning therapy 14 days before anticipated onset of menstruation and continued to the onset of menses); over the first month, may increase to usual effective dose of 20 mg once daily during the luteal phase; in a subsequent menstrual cycle, a further increase to 30 mg/day during the luteal phase may be necessary in some patients for optimal response (Ref).

Symptom-onset dosing regimen (off-label dosing): Oral: Limited data available: Initial 10 mg once daily from the day of symptom onset until a few days after the start of menses; over the first month, may increase dose based on response and tolerability up to 20 mg/day (Ref).

Social anxiety disorder

Social anxiety disorder (off-label use): Oral: Initial: 10 to 20 mg once daily; after ~6 weeks may gradually increase dose based on response and tolerability in 10 mg increments at intervals of ≥1 week up to 60 mg/day (Ref).

Dosing conversion:

Delayed release (once-weekly formulation): Immediate-release fluoxetine 20 mg/day = delayed-release fluoxetine 90 mg/week. When converting from immediate-release fluoxetine daily dosing, initiate delayed-release fluoxetine (90 mg once weekly) 7 days after the last 20 mg/day dose of immediate-release fluoxetine. Patients must be stabilized on immediate-release fluoxetine 20 mg once daily prior to switching.

Olanzapine/fluoxetine fixed-dose combination: When using individual components of fluoxetine with olanzapine rather than fixed-dose combination product, corresponding approximate dosage equivalents are as follows:

Olanzapine 2.5 mg + fluoxetine 20 mg = combination strength 3/25

Olanzapine 5 mg + fluoxetine 20 mg = combination strength 6/25

Olanzapine 12.5 mg + fluoxetine 20 mg = combination strength 12/25

Olanzapine 5 mg + fluoxetine 50 mg = combination strength 6/50

Olanzapine 12.5 mg + fluoxetine 50 mg = combination strength 12/50

Discontinuation of therapy: When discontinuing antidepressant treatment that has lasted for >3 weeks, gradually taper the dose (eg, over 1 to 4 weeks) to minimize withdrawal symptoms and detect re-emerging symptoms (Ref). Reasons for a slower taper (eg, over 4 weeks) include prior history of antidepressant withdrawal symptoms or high doses of antidepressants (Ref). If necessary, some clinicians allow for abrupt discontinuation based on fluoxetine's long half-life (Ref). If intolerable withdrawal symptoms occur, resume the previously prescribed dose and/or decrease dose at a more gradual rate (Ref). Select patients (eg, those with a history of discontinuation syndrome) on long-term treatment (>6 months) may benefit from tapering over >3 months (Ref). Evidence supporting ideal taper rates is limited (Ref).

Switching antidepressants: Evidence for ideal antidepressant switching strategies is limited; strategies include cross-titration (gradually discontinuing the first antidepressant while at the same time gradually increasing the new antidepressant) and direct switch (abruptly discontinuing the first antidepressant and then starting the new antidepressant at an equivalent dose or lower dose and increasing it gradually). Cross-titration (eg, over 1 to 4 weeks depending upon sensitivity to discontinuation symptoms and adverse effects) is standard for most switches, but is contraindicated when switching to or from an MAOI. A direct switch may be an appropriate approach when switching to another agent in the same or similar class (eg, when switching between two SSRIs), when the antidepressant to be discontinued has been used for <1 week, or when the discontinuation is for adverse effects. When choosing the switch strategy, consider the risk of discontinuation symptoms, potential for drug interactions, other antidepressant properties (eg, half-life, adverse effects, and pharmacodynamics), and the degree of symptom control desired (Ref).

Switching to or from an MAOI:

Allow 14 days to elapse between discontinuing an MAOI and initiation of fluoxetine.

Allow 5 weeks to elapse between discontinuing fluoxetine and initiation of an MAOI.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Altered kidney function: No dosage adjustment necessary for any degree of kidney dysfunction (Ref).

Hemodialysis, intermittent (thrice weekly): Not significantly dialyzed (fluoxetine and its metabolite) (Ref): No supplemental dose or dosage adjustment necessary (Ref).

Peritoneal dialysis: Unlikely to be dialyzed (highly protein bound): No dosage adjustment necessary (Ref).

CRRT: No dosage adjustment necessary (Ref).

PIRRT (eg, sustained, low-efficiency diafiltration): No dosage adjustment necessary (Ref).

Dosing: Hepatic Impairment: Adult

Use lower doses (up to 50% reduction) and less frequent dosing intervals in patients with cirrhosis and chronic liver disease; use with caution (Ref).

Dosing: Pediatric

(For additional information see "Fluoxetine: Pediatric drug information")

Note: Unless otherwise specified, pediatric dosing is based on the fluoxetine (eg, Prozac) immediate-release product. When using oral solutions, multiple concentrations may be available (commercially available [4 mg/mL] and compounded solution [eg, 1 mg/mL, 2 mg/mL]); precautions should be taken to verify appropriate product selection and avoid confusion between the different concentrations; dose should be clearly presented as mg.

Anxiety disorders

Anxiety disorders: Limited data available:

Note: Fluoxetine therapy should be initiated at a low dose with a slow titration to reduce the potential for behavioral activation/agitation that may occur with therapy initiation particularly in younger children. Conservatively, fluoxetine dose titration at 3- to 4-week intervals has been suggested due to its long half-life; however, some patients with more severe symptoms may require more rapid titration; in trials, dose titration in weekly increments has been reported (Ref).

Generalized anxiety, separation anxiety, panic disorders:

Note: In pediatric patients, selective serotonin reuptake inhibitor (SSRI) therapy is considered first-line pharmacologic treatment for moderate to severe anxiety disorders in combination with cognitive behavioral therapy (CBT); of the SSRIs with positive pediatric data evaluated in the AHRQ/Mayo review (fluoxetine, fluvoxamine, paroxetine, and sertraline), a preferred SSRI has not been defined; therapeutic selection should be based on pharmacokinetic and pharmacodynamic data, patient tolerability, cost, and unique risks/precautions with specific agents (Ref).

Children 6 to <12 years: Oral: Immediate release: Initial: 5 mg once daily, may slowly titrate as needed; suggested target dose range: 10 to 20 mg once daily; maximum daily dose: 40 mg/day (Ref).

Children ≥12 years and Adolescents: Oral: Immediate release: Initial: 10 mg once daily, may slowly titrate as needed; suggested target dose range: 20 to 40 mg once daily; usual maximum daily dose: 60 mg/day although use of doses up to 80 mg/day has been reported (Ref).

Selective mutism:

Limited data available: Children ≥5 years and Adolescents: Oral: Initial: 5 or 10 mg once daily for ≥7 days, then increase by doubling dose to 10 or 20 mg once daily for 7 days; may further titrate in 20 mg/day increments, if needed, every 2 weeks; maximum daily dose: 60 mg/day (Ref). Dosing is based on an open-label study of 21 pediatric patients (age: 5 to 14 years); positive responses were reported in 76% of patients and required a dose of at least 20 mg/day; mean final dose: 28.1 mg/day (1.1 mg/kg/day) (Ref) and a small (n= 5) single-case design, placebo-controlled trial (ages: 5 to 14 years) with a final dose of 20 mg/day (Ref). To fully assess therapeutic response, a therapeutic trial of at least 9 to 12 weeks or longer has been suggested (Ref).

Anorexia nervosa

Anorexia nervosa: Limited data available; efficacy results variable:

Note: Use in combination with psychosocial intervention or CBT; SSRI antidepressants have not been shown effective during the acute phases of illness; however, they may be considered for comorbid mental health conditions once weight has been restored (Ref).

Adolescents: Oral: Immediate release: Initial: 20 mg once daily; may titrate in 20 mg increments (similar to other indications in adolescents) at monthly intervals; typical reported dosing range: 20 to 40 mg/day; reported maximum daily dose: 60 mg/day (Ref). Dosing based on a small, prospective, double-blind, placebo-controlled trial of 35 patients (fluoxetine: n=16; mean age: 23 ± 9 years) which showed reduced relapse (increased weight, decrease in symptoms) with 1 year of fluoxetine and mean dose of 38 ± 21 mg/day (Ref). Other randomized controlled trials with similar dosing have not shown fluoxetine therapy effective (Ref).

Bulimia nervosa

Bulimia nervosa: Limited data available: Note: Antidepressant therapy is recommended to target symptoms of obsessionality, anxiety, and depression in combination with CBT (Ref).

Children ≥12 years and Adolescents: Oral: Immediate release: Initial: 20 mg once daily for 3 days, then 40 mg once daily for 3 days, then 60 mg once daily; dosing based on an open-label study of 10 pediatric patients (age: 12 to 18 years) which showed significant decrease in number of weekly purges; other reports describe use in adolescents (Ref).

Depression

Depression:

Note: In the management of depression in children and adolescents, if pharmacotherapy is deemed necessary with/without psychotherapeutic interventions, an SSRI should be used first-line; fluoxetine has the strongest efficacy evidence and is preferred as first-line SSRI option in absence of drug-drug interactions, risk factors for bipolar comorbidity, or family (eg, parent, sibling) history of poor response to fluoxetine (Ref). Therapy should be initiated at a low dose and titrated every 1 to 2 weeks (Ref).

Children 8 to <12 years: Oral: Immediate release: Initial: 5 or 10 mg once daily; usual daily dose: 10 mg once daily; if needed, may increase dose to 20 mg once daily after 1 to 2 weeks; some pediatric patients may require higher doses up to 40 mg/day; maximum daily dose: 40 mg/day (Ref).

Children ≥12 years and Adolescents: Oral: Immediate release: Initial: 10 to 20 mg once daily; may increase in 10 to 20 mg increments every 1 to 2 weeks; usual effective dose: 20 to 40 mg once daily; maximum daily dose: 60 mg/day (Ref).

Depression associated with bipolar I disorder

Depression associated with bipolar I disorder (in combination with olanzapine):

Children ≥10 years and Adolescents: Oral: Immediate release: Initial: 20 mg in the evening; adjust dose, if needed, as tolerated; safety of fluoxetine doses >50 mg in combination with doses >12 mg of olanzapine has not been studied in pediatrics.

Note: When using individual components of fluoxetine with olanzapine rather than fixed-dose combination product (Symbyax), approximate dosage correspondence is as follows:

Olanzapine 2.5 mg + fluoxetine 20 mg = Symbyax 3/25.

Olanzapine 5 mg + fluoxetine 20 mg = Symbyax 6/25.

Olanzapine 12.5 mg + fluoxetine 20 mg = Symbyax 12/25.

Olanzapine 5 mg + fluoxetine 50 mg = Symbyax 6/50.

Olanzapine 12.5 mg + fluoxetine 50 mg = Symbyax 12/50.

Obsessive-compulsive disorder

Obsessive-compulsive disorder (OCD):

Note: In the management of OCD in children and adolescents, if pharmacotherapy deemed necessary it should be in combination with CBT and an SSRI should be used first-line; a preferred agent has not been identified (Ref).

Children preschool to <7 years: Limited data available:

Note: Use should be reserved for patients with moderate to severe symptoms which cause significant distress or significant impairment in the child's relationships, daily routine at home, or child care setting, and continue despite psychotherapeutic interventions (Ref).

Oral: Immediate release: 2.5 to 5 mg once daily initially; continue for 10 to 12 weeks to assess initial response; monitor closely (Ref).

Children ≥7 years and Adolescents: Oral: Immediate release (Ref).

Lower weight Children: Initial: 5 to 10 mg once daily; if needed, may increase dose after several weeks; usual daily dose: 20 to 30 mg/day; minimal experience with doses >20 mg/day; no experience with doses >60 mg/day.

Higher weight Children and Adolescents: Initial: 10 mg once daily; increase dose to 20 mg once daily after 2 weeks; may increase dose after several more weeks; usual daily dose: 20 to 60 mg/day; however, doses of 80 mg/day may be considered in some cases.

Discontinuation of therapy: Consider planning antidepressant discontinuation for lower-stress times, recognizing non-illness-related factors could cause stress or anxiety and be misattributed to antidepressant discontinuation (Ref). Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of discontinuation syndromes (withdrawal) and allow for the detection of reemerging disease state symptoms (eg, relapse). Evidence supporting ideal taper rates after illness remission is limited. APA and NICE guidelines suggest tapering therapy over at least several weeks with consideration to the half-life of the antidepressant; antidepressants with a shorter half-life may need to be tapered more conservatively. After long-term (years) antidepressant treatment, WFSBP guidelines recommend tapering over 4 to 6 months, with close monitoring during and for 6 months after discontinuation. If intolerable discontinuation symptoms occur following a dose reduction, consider resuming the previously prescribed dose and/or decrease dose at a more gradual rate (Ref).

Switching antidepressants: Evidence for ideal antidepressant switching strategies in pediatric patients is sparse; strategies described in pediatric guidelines include a conservative approach (tapering and discontinuing the first SSRI before adding the second) and cross-titration (gradually discontinuing the first antidepressant while at the same time gradually increasing the new antidepressant). While consensus does not exist regarding which approach to utilize, it is important to note that the conservative approach runs the risk for exacerbation of symptoms or discontinuation syndrome; cross-titration may avoid these risks (Ref). Cross-titration (eg, over 1 to 4 weeks depending upon sensitivity to discontinuation symptoms and adverse effects) is standard for most switches, but is contraindicated when switching to or from a monamine oxidase inhibitors. While not as common of a strategy, a direct switch may be considered when switching to another agent in the same or similar class (eg, when switching between 2 SSRIs), when the antidepressant to be discontinued has been used for <1 week, or when the discontinuation is for adverse effects. When choosing the switch strategy, consider the risk of discontinuation symptoms, potential for drug interactions, other antidepressant properties (eg, half-life, adverse effects, pharmacodynamics), and the degree of symptom control desired (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

Children ≥7 years and Adolescents: Adjustment not routinely needed. With chronic administration, additional accumulation of fluoxetine or norfluoxetine may occur in patients with severely impaired renal function. Based on experience in adult patients, not removed by hemodialysis; use of lower dose or less frequent dosing is not usually necessary.

Dosing: Hepatic Impairment: Pediatric

Children ≥7 years and Adolescents: Elimination half-life of fluoxetine is prolonged in patients with hepatic impairment; lower doses or less frequent administration are recommended.

Dosing: Older Adult

Major depressive disorder (unipolar): Oral: Some patients may require an initial dose of 10 mg once daily with dosage increases of 10 to 20 mg every several weeks as tolerated; should not be taken at night unless patient experiences sedation. Refer to adult dosing; use with caution given the long half-life of fluoxetine.

Dosing conversion: Refer to adult dosing.

Discontinuation of therapy: Refer to adult dosing.

Switching antidepressants: Refer to adult dosing.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Capsule, Oral:

PROzac: 10 mg, 20 mg, 40 mg

Generic: 10 mg, 20 mg, 40 mg

Capsule Delayed Release, Oral:

Generic: 90 mg

Solution, Oral:

Generic: 20 mg/5 mL (5 mL, 120 mL)

Tablet, Oral:

Sarafem: 10 mg [DSC], 20 mg [DSC] [contains fd&c yellow #6(sunset yellow)alumin lake, quinoline (d&c yellow #10) aluminum lake]

Generic: 10 mg, 20 mg, 60 mg

Generic Equivalent Available: US

Yes

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Capsule, Oral:

PROzac: 10 mg, 20 mg [contains butylparaben, edetate (edta) calcium disodium, fd&c blue #1 (brilliant blue), methylparaben, propylparaben]

Generic: 10 mg, 20 mg, 40 mg, 60 mg

Solution, Oral:

Generic: 20 mg/5 mL (120 ea, 120 mL)

Medication Guide and/or Vaccine Information Statement (VIS)

An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:

Fluoxetine tablets: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202133s012lbl.pdf#page=35

Prozac: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/018936s109lbl.pdf#page=26

Sarafem: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021860s015lbl.pdf#page=32

Administration: Adult

Administer without regard to meals.

Bipolar I disorder and treatment-resistant depression: Take once daily in the evening.

Major depressive disorder and obsessive compulsive disorder: Once daily doses should be taken in the morning, or twice daily (morning and noon).

Bulimia: Take once daily in the morning.

Bariatric surgery: Capsule, delayed release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. Delayed-release capsule cannot be opened. Switch to IR tablet or oral solution dosed daily.

Administration: Pediatric

Oral: May be administered without regard to food. For most pediatric uses (ie, anxiety, obsessive-compulsive disorder, depression, anorexia, bulimia), doses should be administered in the morning. When used concomitantly with olanzapine for bipolar I disorder and treatment-resistant depression, doses should be administered in the evening.

Use: Labeled Indications

Bipolar major depression (excluding Sarafem): Acute treatment of major depressive episodes (in combination with olanzapine [preferred], other antipsychotics, or antimanic agents) (WFSBP [Grunze 2010]) associated with bipolar I disorder

Bulimia nervosa (excluding Sarafem): Acute and maintenance treatment of binge eating and vomiting behaviors in patients with moderate to severe bulimia nervosa

Major depressive disorder (unipolar) (excluding Sarafem): Acute and maintenance treatment of unipolar major depressive disorder (MDD)

Obsessive-compulsive disorder (excluding Sarafem): Acute and maintenance treatment of obsessions and compulsions in patients with obsessive-compulsive disorder

Panic disorder (excluding Sarafem): Acute treatment of panic disorder with or without agoraphobia

Premenstrual dysphoric disorder (Sarafem only): Treatment of premenstrual dysphoric disorder

Treatment-resistant depression (excluding Sarafem): Acute treatment of treatment-resistant depression (patients with MDD who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode) in combination with olanzapine or other antipsychotics (APA 2010)

Use: Off-Label: Adult

Binge eating disorder; Body dysmorphic disorder; Fibromyalgia, refractory; Generalized anxiety disorder; Posttraumatic stress disorder; Premature ejaculation; Selective mutism; Social anxiety disorder

Medication Safety Issues
Sound-alike/look-alike issues:

FLUoxetine may be confused with DULoxetine, famotidine, Feldene, fluconazole, fluvastatin, fluvoxaMINE, fosinopril, furosemide, Loxitane [DSC], PARoxetine, thiothixene, vortioxetine

PROzac may be confused with Paxil, Prelone, PriLOSEC, Prograf, Proscar, ProSom, Provera

Sarafem may be confused with Serophene

Older Adult: High-Risk Medication:

Beers Criteria: Selective Serotonin Reuptake Inhibitors (SSRIs) are identified in the Beers Criteria as a potentially inappropriate medications to be used with caution in patients 65 years and older due to the potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium concentration closely when initiating or adjusting the dose in older adults (Beers Criteria [AGS 2019]).

International issues:

Reneuron [Spain] may be confused with Remeron brand name for mirtazapine [US, Canada, and multiple international markets]

Adverse Reactions (Significant): Considerations
Activation of mania or hypomania

Antidepressants (when used as monotherapy) may precipitate a mixed/manic episode in patients with bipolar disorder. Treatment-emergent mania or hypomania in patients with unipolar major depressive disorder (MDD) have been reported, as many cases of bipolar disorder present in episodes of MDD (Ref).

Mechanism: Non-dose-related; idiosyncratic. Unclear to what extent mood switches represent an uncovering of unrecognized bipolar disorder or a more direct pharmacologic effect independent of diagnosis (Ref).

Onset: Varied; a systematic review observed that the risk of switching increased significantly within the initial 2 years of antidepressant treatment in patients with unipolar MDD receiving an antidepressant as monotherapy, but not thereafter (up to 4.6 years) (Ref).

Risk factors:

• Family history of bipolar disorder (Ref)

• Depressive episode with psychotic symptoms (Ref)

• Younger age at onset of depression (Ref)

• Antidepressant resistance (Ref)

• Female sex (Ref)

Bleeding risk

Selective serotonin reuptake inhibitors (SSRIs), including fluoxetine, may increase the risk of bleeding, particularly if used concomitantly with antiplatelets and/or anticoagulants in adult and pediatric patients. Multiple observational studies have found an association with SSRI use and a variety of bleeding complications, ranging from bruise, hematoma, petechia, purpuric disease, and epistaxis to cerebrovascular accident, upper gastrointestinal hemorrhage, intracranial hemorrhage, postpartum hemorrhage, and intraoperative bleeding, although conflicting evidence also exists (Ref).

Mechanism: Possibly via decreased platelet serotonin concentrations and inhibition of serotonin-mediated platelet activation leading to subsequent platelet dysfunction. Fluoxetine is considered to display high affinity for the serotonin receptor (Ref). SSRIs may also increase gastric acidity, which can increase the risk of GI bleeding (Ref).

Onset: Varied; bleeding risk is likely delayed for several weeks until SSRI-induced platelet serotonin depletion becomes clinically significant (Ref); although the onset of bleeding may be more unpredictable if patients are taking concomitant antiplatelets, anticoagulants, or nonsteroidal anti-inflammatory drugs (NSAIDs). For upper GI bleeding, some studies have found risk to be the highest in the first 28 to 30 days (Ref), whereas another study reported a median time of onset of 25 weeks (Ref).

Risk factors:

Concomitant use of anticoagulants and/or antiplatelets (Ref)

Preexisting platelet dysfunction or coagulation disorders (eg, von Willebrand factor) (Ref)

Concomitant use of NSAIDs increase the risk for upper GI bleeding (Ref)

Fragility fractures

Limited data from observational studies involving mostly older adults (≥50 years of age) suggest selective serotonin reuptake inhibitors (SSRIs) are associated with an increased risk of bone fractures (Ref).

Mechanism: Time-related; mechanism not fully elucidated; postulated to be through a direct effect by SSRIs on bone metabolism via interaction with 5-HT and osteoblast, osteocyte, and/or osteoclast activity (Ref). SSRIs may also contribute to fall risk, contributing to the incidence of fractures (Ref).

Onset: Delayed; risk appears to increase after initiation and may continue to increase with long-term use. A meta-analysis found risk of fracture increased from 2.9% over 1 year to 5.4% over 2 years; within 5 years, risk increased to 13.4% (Ref).

Risk factors:

Long-term use may be a risk factor (Ref)

Hypersensitivity reactions

A wide variety of hypersensitivity reactions have been reported rarely with fluoxetine, including severe systemic reactions; reactions include dermatitis, urticaria, angioedema, eosinophilia, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), serum-like sickness reaction, vasculitis (eg, leukocytoclastic vasculitis, Henoch-Schönlein purpura), and certain pulmonary inflammatory diseases (eg, hypersensitivity pneumonitis, pulmonary granuloma) (Ref).

Mechanism: Non-dose-related; immunologic. Severe cutaneous adverse reactions, namely SJS/TEN, DRESS, acute generalized exanthematous pustulosis), are delayed type IV hypersensitivity reactions involving a T-cell mediated drug-specific immune response (Ref).

Onset: Intermediate; in the majority of cases, onset of symptoms generally occurred from 1 to 4 weeks after initiation of therapy (Ref).

Hyponatremia

Selective serotonin reuptake inhibitors (SSRIs) are associated with syndrome of inappropriate antidiuretic hormone secretion (SIADH) and/or hyponatremia, including severe cases, predominantly in the elderly (Ref). Hyponatremia is reversible with discontinuation of therapy (Ref).

Mechanism: May cause SIADH via release of antidiuretic hormone (ADH) (Ref) or may cause nephrogenic SIADH by increasing the sensitivity of the kidney to ADH (Ref).

Onset: Intermediate; usually develops within the first few weeks of treatment (Ref).

Risk factors:

• Older age (Ref)

• Females (Ref)

• Concomitant use of diuretics (Ref)

• Low body weight (Ref)

• Lower baseline serum sodium concentration (Ref)

• Volume depletion (Ref)

• History of hyponatremia (potential risk factors) (Ref)

• Symptoms of psychosis (potential risk factors) (Ref)

Ocular effects

Selective serotonin reuptake inhibitors (SSRIs) are associated with acute angle-closure glaucoma (AACG) in case reports and a case-controlled study. AACG may cause symptoms including eye pain, changes in vision, swelling, and redness, which can rapidly lead to permanent blindness if not treated (Ref). In addition, SSRIs may be associated with an increased risk of cataract development (Ref).

Mechanism: AACG: Unclear; hypothesized SSRIs may increase the intraocular pressure via serotonergic effects on ciliary body muscle activation and pupil dilation (Ref).

Risk factors:

For AACG:

Females (Ref)

≥50 years of age (slight increase) (Ref)

Hyperopia (slight increase) (Ref)

Personal or family history of AACG (Ref)

Inuit or Asian descent (Ref)

Serotonin syndrome

Serotonin syndrome has been reported and typically occurs with coadministration of multiple serotonergic drugs but can occur following a single serotonergic agent at therapeutic doses, particularly with fluoxetine use (Ref). The diagnosis of serotonin syndrome is made based on the Hunter Serotonin Toxicity Criteria (Ref) and may result in a spectrum of symptoms, such as anxiety, agitation, confusion, delirium, hyperreflexia, muscle rigidity, myoclonus, tachycardia, tachypnea, and tremor. Severe cases may cause hyperthermia, significant autonomic instability (ie, rapid and severe changes in blood pressure and pulse), coma, and seizures (Ref).

Mechanism: Dose-related; overstimulation of serotonin receptors by serotonergic agents (Ref).

Onset: Rapid; in the majority of cases (74%), onset occurred within 24 hours of treatment initiation, overdose, or change in dose (Ref).

Risk factors:

• Concomitant use of drugs that increase serotonin synthesis, block serotonin reuptake and/or impair serotonin metabolism (eg, monamine oxidase inhibitors [MAOIs]). Of note, concomitant use of some serotonergic agents, such as MAOIs, are contraindicated.

Sexual dysfunction

Selective serotonin reuptake inhibitors (SSRIs) are commonly associated with sexual disorders in both men and women. The following adverse reactions have been associated with SSRI use: Ejaculatory delay, orgasm disturbance, anorgasmia, erectile dysfunction, decreased libido, and loss of libido (Ref). Priapism and decreased genital anesthesia have also been reported (Ref).

Mechanism: Increases in serotonin may affect other hormones and neurotransmitters involved in sexual function; in particular, testosterone's effect on sexual arousal and dopamine's role in achieving orgasm (Ref).

Onset: Varied; one longitudinal study observed an onset of sexual dysfunction within the first 6 weeks of treatment with fluoxetine (Ref).

Risk factors:

• Depression (sexual dysfunction is commonly associated with depression; SSRI-associated sexual dysfunction may be difficult to differentiate in treated patients) (Ref)

Suicidal thinking and behavior

Antidepressants are associated with an increased risk of suicidal ideation and suicidal tendencies in pediatric and young adult patients (18 to 24 years of age) in short-term studies. In adults >24 years of age, short-term studies did not show an increased risk of suicidal thinking and behavior, and in older adults ≥65 years of age a decreased risk was observed. Although data have yielded inconsistent results regarding the association of antidepressants and risk of suicide, particularly among adults, collective evidence shows a trend of an elevated risk of suicidality in younger age groups (Ref). Of note, the risk of a suicide attempt is inherent in major depression and may persist until remission occurs.

Mechanism: Not established; one of several postulated mechanisms is antidepressants may energize suicidal patients to act on impulses; another suggests that antidepressants may produce a worsening of depressive symptoms leading to the emergence of suicidal thoughts and actions (Ref).

Onset: Varied; increased risk observed in short-term studies (ie, <4 months) in pediatric and young adults; it is unknown whether this risk extends to longer-term use (ie, >4 months).

Risk factors:

• Children and adolescents (Ref)

• Depression (risk of suicide associated with major depression and may persist until remission occurs)

Withdrawal syndrome

Withdrawal syndrome, consisting of both somatic symptoms (eg, dizziness, chills, light-headedness, vertigo, shock-like sensations, paresthesia, fatigue, headache, nausea, tremor, diarrhea, visual disturbances) and psychological symptoms (eg, anxiety, agitation, confusion, insomnia, irritability, mania), have been reported, primarily following abrupt discontinuation. Withdrawal symptoms may also occur following gradual tapering (Ref).

Mechanism: Withdrawal; due to reduced availability of serotonin in the CNS with decreasing levels of the selective serotonin reuptake inhibitor. Other neurotransmission systems, including increased glutamine and dopamine, may also be affected as well as the hypothalamic-pituitary-adrenal axis (Ref).

Onset: Intermediate; expected onset is 1 to 10 days (following either abrupt or tapered discontinuation) (Ref).

Risk factors:

• Abrupt discontinuation (rather than gradual dosage reduction) of an antidepressant treatment that has lasted >3 weeks, particularly a drug with a half-life <24 hours (eg, paroxetine, venlafaxine) (Ref)

• Prior history of antidepressant withdrawal symptoms (Ref)

• High dose (Ref)

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. As reported in adults, unless otherwise noted.

>10%:

Endocrine & metabolic: Decreased libido (1% to 11%) (table 1)

Fluoxetine: Adverse Reaction: Decreased Libido

Drug (Fluoxetine)

Placebo

Indication

Number of Patients (Fluoxetine)

Number of Patients (Placebo)

5%

1%

Bulimia

450

267

3%

N/A

MDD

1728

975

11%

2%

OCD

266

89

1%

2%

Panic disorder

425

342

Gastrointestinal: Anorexia (4% to 17%), diarrhea (8% to 18%), nausea (12% to 29%), xerostomia (9% to 12%)

Genitourinary: Sexual disorder (literature suggests an incidence ranging from 54% to 58%; can persist after discontinuation) (Higgins 2010; Montejo 2001; Montejo-Gonzalez 1997; Csoka 2006)

Nervous system: Anxiety (6% to 15%), drowsiness (5% to 17%; literature suggests it is more common in adults compared to children and adolescents) (Safer 2006), headache (21%), insomnia (10% to 33%), nervousness (8% to 14%), yawning (≤11%)

Neuromuscular & skeletal: Asthenia (9% to 21%), tremor (3% to 13%)

Respiratory: Pharyngitis (10% to 11%)

1% to 10%:

Cardiovascular: Chest pain (≥1%), hypertension (≥1%), palpitations (≥1%), prolonged QT interval on ECG (≥1%; QTcF ≥450 msec3), vasodilation (1% to 5%)

Dermatologic: Diaphoresis (7% to 8%), pruritus (3%), skin rash (2% to 6%) (table 2)

Fluoxetine: Adverse Reaction: Skin Rash

Drug (Fluoxetine)

Placebo

Indication

Number of Patients (Fluoxetine)

Number of Patients (Placebo)

4%

4%

Bulimia

450

267

4%

3%

MDD

1728

975

6%

3%

OCD

266

89

2%

2%

Panic disorder

425

342

Endocrine & metabolic: Heavy menstrual bleeding (children and adolescents: ≥2%), increased thirst (children and adolescents: ≥2%), weight loss (2%)

Gastrointestinal: Constipation (5%), dysgeusia (≥1%), dyspepsia (6% to 10%), flatulence (3%), increased appetite (≥1%), vomiting (3%; literature suggests prevalence is higher in adolescents compared to adults and is two- to threefold more prevalent in children compared to adults) (Safer 2006)

Genitourinary: Ejaculatory disorder (2% to 7%) (table 3), impotence (≤7%), urinary frequency (children and adolescents: ≥2%), urination disorder (≥1%)

Fluoxetine: Adverse Reaction: Ejaculatory Disorder

Drug (Fluoxetine)

Placebo

Indication

Number of Patients (Fluoxetine)

Number of Patients (Placebo)

7%

N/A

Bulimia

14

1

7%

N/A

OCD

116

43

2%

1%

Panic disorder

162

121

Nervous system: Abnormal dreams (5%), abnormality in thinking (2%), agitation (children and adolescents: ≥2%), amnesia (≥1%), chills (≥1%), dizziness (9%), emotional lability (≥1%), personality disorder (children and adolescents: ≥2%), sleep disorder (≥1%)

Neuromuscular & skeletal: Hyperkinetic muscle activity (children and adolescents: ≥2%)

Ophthalmic: Visual disturbance (2%)

Otic: Otalgia (≥1%), tinnitus (≥1%)

Respiratory: Epistaxis (children and adolescents: ≥2%), flu-like symptoms (8% to 10%), sinusitis (5% to 6%)

<1%:

Cardiovascular: Acute myocardial infarction, angina pectoris, cardiac arrhythmia, cardiac failure, edema, hypotension, orthostatic hypotension, syncope, vasculitis

Dermatologic: Acne vulgaris, alopecia, ecchymoses, psoriasis (new onset) (Tan Pei Lin 2010), skin photosensitivity

Endocrine & metabolic: Albuminuria, amenorrhea, gout, hypercholesterolemia, hypothyroidism, increased libido

Gastrointestinal: Aphthous stomatitis, bloody diarrhea, bruxism, cholelithiasis, colitis, duodenal ulcer, esophageal ulcer, gastritis, gastroenteritis, gastrointestinal ulcer, glossitis, hematemesis, melena, peptic ulcer

Genitourinary: Gynecological bleeding

Hematologic & oncologic: Anemia, petechia, purpuric rash, upper gastrointestinal hemorrhage (Wee 2017)

Hepatic: Abnormal hepatic function tests, hepatitis (Capellà 1999; Friedenberg 1996)

Nervous system: Akathisia, anorgasmia (Kline 1989), ataxia, balance impairment, delusion, depersonalization, euphoria, extrapyramidal reaction (rare), hostility, hypertonia, migraine, myoclonus, obsessive compulsive disorder (trichotillomania) (Yektaş 2017), paranoid ideation, seizure (Hargrave 1992; Levine 1994), suicidal ideation (Teicher 1990), suicidal tendencies

Neuromuscular & skeletal: Arthritis, bursitis, lower limb cramp, ostealgia

Ophthalmic: Mydriasis

Respiratory: Asthma, laryngeal edema

Postmarketing:

Cardiovascular: Atrial fibrillation, cerebrovascular accident, pulmonary embolism, ventricular tachycardia (including torsades de pointes)

Dermatologic: Dermatitis (Agrawal 2019), erythema multiforme, erythema nodosum, exfoliative dermatitis, Stevens-Johnson syndrome (rare: <1%) (Agrawal 2019), toxic epidermal necrolysis (rare: <1%) (Jonsson 2008)

Endocrine & metabolic: Gynecomastia, hyperprolactinemia, hypoglycemia, hypokalemia, hyponatremia (literature suggests incidence among selective serotonin reuptake inhibitors [SSRIs] ranges from <1% to as high as 32%) (Jacob 2006; Kaya 2016), SIADH (rare: <1%) (Blacksten 1993)

Gastrointestinal: Esophagitis, pancreatitis

Genitourinary: Priapism (rare: <1%) (Javed 1996), sexual difficulty (decreased genital sensation) (Michael 2000)

Hematologic & oncologic: Aplastic anemia, bruise (rare: <1%) (Pai 1996), hemolytic anemia (immune-related), Henoch-Schonlein purpura (rare: <1%) (Süleyman 2016), immune thrombocytopenia, pancytopenia, thrombocytopenia (Yucel 2015)

Hepatic: Cholestatic jaundice, hepatic failure, hepatic necrosis, hepatotoxicity (Agrawal 2019)

Hypersensitivity: Hypersensitivity reaction (rare: <1%) (Beer 1994), nonimmune anaphylaxis

Immunologic: Drug reaction with eosinophilia and systemic symptoms (rare: <1%) (Vignesh 2017), serum-like sickness reaction (Miller 1989)

Nervous system: Dystonia (Bilen 2008), hallucination, hyperactive behavior (including agitation, hyperactivation, hyperkinesis, restlessness; occurring in children at a two- to threefold higher incidence compared to adolescents) (Safer 2006), hypomania (rare: <1%) (Jerome 1991), mania (rare: <1%) (Settle 1984), memory impairment, neuroleptic malignant syndrome, serotonin syndrome (rare: <1%) (Patel 2016), tardive dyskinesia (Dubovsky 1996), violent behavior

Neuromuscular & skeletal: Dyskinesia (Mander 1994), laryngospasm, linear skeletal growth rate below expectation (children) (Weintrob 2006), lupus-like syndrome

Ophthalmic: Acute angle-closure glaucoma (rare: <1%) (Ahmad 1991), cataract, optic neuritis

Renal: Renal failure syndrome

Respiratory: Eosinophilic pneumonitis, hypersensitivity pneumonitis (rare: <1%) (Gonzalez-Rothi 1995), hyperventilation, pulmonary fibrosis, pulmonary granuloma (rare: <1%) (de Kerviler 1996), pulmonary hypertension

Contraindications

Hypersensitivity to fluoxetine or any component of the formulation; use of MAO inhibitors intended to treat psychiatric disorders (concurrently, within 5 weeks of discontinuing fluoxetine, or within 2 weeks of discontinuing the MAO inhibitor); initiation of fluoxetine in a patient receiving linezolid or intravenous methylene blue; use with pimozide or thioridazine (Note: Thioridazine should not be initiated until 5 weeks after the discontinuation of fluoxetine.)

Canadian labeling: Additional contraindications (not in the US labeling): Initiation of fluoxetine within 2 weeks of thioridazine discontinuation

Warnings/Precautions

Concerns related to adverse effects:

• CNS depression: Has a low potential to impair cognitive or motor performance; caution operating hazardous machinery or driving.

• QT prolongation: QT prolongation and ventricular arrhythmia, including torsades de pointes, have occurred. Use with caution in patients with risk factors for QT prolongation (eg, congenital long QT syndrome, history of prolonged QT, family history of prolonged QT or sudden cardiac death), other conditions that predispose to arrhythmias (eg, hypokalemia, hypomagnesemia, recent myocardial infarction [MI], uncompensated heart failure, bradyarrhythmias or other arrhythmias, concomitant use of other agents that prolong QT interval), or increased fluoxetine exposure (eg, overdose, hepatic impairment, use of CYP2D6 inhibitors, poor CYP2D6 metabolizer status, concomitant use of other highly protein-bound drugs). Consider ECG monitoring when initiating therapy in patients with risk factors for QT prolongation and ventricular arrhythmia. Consider discontinuing fluoxetine if ventricular arrhythmia suspected and initiate cardiac evaluation.

Disease-related concerns:

• Cardiovascular disease: Use with caution in patients with a history of MI or unstable heart disease; experience in these patients is limited.

• Hepatic impairment: Use with caution in patients with hepatic impairment; clearance is decreased and half-life and plasma concentrations are increased; a lower dosage may be needed in patients with cirrhosis. However, selective serotonin reuptake inhibitors such as fluoxetine are considered the safest antidepressants to use in chronic liver disease because of their relative lack of side effects and high therapeutic index (Mullish 2014).

• Renal impairment: Use with caution in patients with severe renal impairment.

• Seizure disorders: Use with caution in patients with a previous seizure disorder or conditions predisposing to seizures such as brain damage or alcoholism.

Special populations:

• Older adult: May also cause agitation, sleep disturbances, and excessive CNS stimulation in older adults. Given the long half-life and nonlinear disposition of the drug, use caution, particularly if they have systemic illness or are receiving multiple drugs for concomitant diseases.

Dosage form specific issues:

• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggest that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.

Other warnings/precautions:

• Long half-life: Due to the long half-life of fluoxetine and its metabolites, the effects and interactions noted may persist for prolonged periods following discontinuation.

Metabolism/Transport Effects

Substrate of CYP1A2 (minor), CYP2B6 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (minor); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; Inhibits CYP2C19 (moderate), CYP2D6 (strong)

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Abrocitinib: Agents with Antiplatelet Properties may enhance the antiplatelet effect of Abrocitinib. Management: Do not use antiplatelet drugs with abrocitinib during the first 3 months of abrocitinib therapy. The abrocitinib prescribing information lists this combination as contraindicated. This does not apply to low dose aspirin (81 mg/day or less). Risk X: Avoid combination

Acalabrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the antiplatelet effect of other Agents with Antiplatelet Properties. Risk C: Monitor therapy

Agents with Blood Glucose Lowering Effects: Selective Serotonin Reuptake Inhibitors may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy

Ajmaline: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Ajmaline. Risk C: Monitor therapy

Alcohol (Ethyl): May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. Management: Patients receiving selective serotonin reuptake inhibitors should be advised to avoid alcohol. Monitor for increased psychomotor impairment in patients who consume alcohol during treatment with selective serotonin reuptake inhibitors. Risk D: Consider therapy modification

Almotriptan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor therapy

Alosetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor therapy

Amphetamines: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors). This could result in serotonin syndrome. Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors) may increase the serum concentration of Amphetamines. Management: Monitor for amphetamine toxicities, including serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability). Initiate amphetamines at lower doses, monitor frequently, and adjust dose as needed. Risk C: Monitor therapy

Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. Risk C: Monitor therapy

Antiemetics (5HT3 Antagonists): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor therapy

Antipsychotic Agents: Serotonergic Agents (High Risk) may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonergic agents may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Risk C: Monitor therapy

Apixaban: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased. Management: Carefully consider risks and benefits of this combination and monitor closely. Risk C: Monitor therapy

ARIPiprazole: CYP2D6 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole. Management: Aripiprazole dose reductions are required for indications other than major depressive disorder. Dose reductions vary based on formulation, initial starting dose, and the additional use of CYP3A4 inhibitors. See full interaction monograph for details. Risk D: Consider therapy modification

ARIPiprazole Lauroxil: CYP2D6 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of ARIPiprazole Lauroxil. Management: Decrease aripiprazole lauroxil dose to next lower strength if used with strong CYP2D6 inhibitors for over 14 days. No dose adjustment needed if using the lowest dose (441 mg) or if a CYP2D6 PM. Max dose is 441 mg if also taking strong CYP3A4 inhibitors. Risk D: Consider therapy modification

Aspirin: Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Aspirin. Risk C: Monitor therapy

Atomoxetine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Atomoxetine. Management: Initiate atomoxetine at a reduced dose (patients who weigh up to 70 kg: 0.5 mg/kg/day; adults or patients who weigh 70 kg or more: 40 mg/day) in patients receiving a strong CYP2D6 inhibitor. Increase to usual target dose after 4 weeks if needed. Risk D: Consider therapy modification

Belzutifan: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Belzutifan. Risk C: Monitor therapy

Bemiparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Bemiparin. Management: Avoid concomitant use of bemiparin with antiplatelet agents. If concomitant use is unavoidable, monitor closely for signs and symptoms of bleeding. Risk D: Consider therapy modification

Brexanolone: Selective Serotonin Reuptake Inhibitors may enhance the CNS depressant effect of Brexanolone. Risk C: Monitor therapy

Brexpiprazole: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Brexpiprazole. Management: Reduce brexpiprazole dose to 50% of usual with strong CYP2D6 inhibitors, reduce to 25% of usual if used with both a strong CYP2D6 inhibitor and a strong or moderate CYP3A4 inhibitor; these recommendations do not apply if treating major depressive disorder Risk D: Consider therapy modification

Brivaracetam: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Brivaracetam. Risk C: Monitor therapy

Bromopride: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Risk X: Avoid combination

Broom: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Broom. Specifically, the concentrations of sparteine, a constituent of broom, may be increased. Risk C: Monitor therapy

BuPROPion: FLUoxetine may enhance the neuroexcitatory and/or seizure-potentiating effect of BuPROPion. BuPROPion may increase the serum concentration of FLUoxetine. Risk C: Monitor therapy

BusPIRone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor therapy

Caplacizumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Caplacizumab. Specifically, the risk of bleeding may be increased. Management: Avoid coadministration of caplacizumab with antiplatelets if possible. If coadministration is required, monitor closely for signs and symptoms of bleeding. Interrupt use of caplacizumab if clinically significant bleeding occurs. Risk D: Consider therapy modification

CarBAMazepine: FLUoxetine may increase the serum concentration of CarBAMazepine. Risk C: Monitor therapy

Carisoprodol: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Carisoprodol. CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Carisoprodol. Risk C: Monitor therapy

Carvedilol: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Carvedilol. Risk C: Monitor therapy

Cephalothin: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased. Risk C: Monitor therapy

Charcoal, Activated: May decrease serum concentrations of the active metabolite(s) of FLUoxetine. Charcoal, Activated may decrease the serum concentration of FLUoxetine. Risk C: Monitor therapy

Chlorpheniramine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Chlorpheniramine. Risk C: Monitor therapy

Cilostazol: CYP2C19 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Cilostazol. CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Cilostazol. Management: Reduce the cilostazol dose to 50 mg twice daily in patients who are also receiving moderate inhibitors of CYP2C19. Monitor clinical response to cilostazol closely. Risk D: Consider therapy modification

Cimetidine: May increase the serum concentration of FLUoxetine. Risk C: Monitor therapy

Citalopram: May enhance the antiplatelet effect of FLUoxetine. Citalopram may enhance the serotonergic effect of FLUoxetine. This could result in serotonin syndrome. FLUoxetine may increase the serum concentration of Citalopram. Management: Limit citalopram dose to a maximum of 20 mg/day. Monitor for signs and symptoms of bleeding, QTc interval prolongation, or serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor) if combined. Risk D: Consider therapy modification

Clarithromycin: FLUoxetine may enhance the QTc-prolonging effect of Clarithromycin. Clarithromycin may increase the serum concentration of FLUoxetine. Risk C: Monitor therapy

CloBAZam: CYP2C19 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of CloBAZam. CYP2C19 Inhibitors (Moderate) may increase the serum concentration of CloBAZam. Risk C: Monitor therapy

Clopidogrel: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel. Risk C: Monitor therapy

CloZAPine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of CloZAPine. Risk C: Monitor therapy

Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and or bleeding may be increased. Risk C: Monitor therapy

Cyclobenzaprine: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor therapy

CYP2D6 Inhibitors (Strong): May increase the serum concentration of FLUoxetine. Risk C: Monitor therapy

Cyproheptadine: May diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Risk C: Monitor therapy

Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel. Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor. Risk C: Monitor therapy

Dapoxetine: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Do not use serotonergic agents (high risk) with dapoxetine or within 7 days of serotonergic agent discontinuation. Do not use dapoxetine within 14 days of monoamine oxidase inhibitor use. Dapoxetine labeling lists this combination as contraindicated. Risk X: Avoid combination

Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Deoxycholic Acid: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. Risk C: Monitor therapy

Desmopressin: Hyponatremia-Associated Agents may enhance the hyponatremic effect of Desmopressin. Risk C: Monitor therapy

Deutetrabenazine: CYP2D6 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Deutetrabenazine. Management: The total daily dose of deutetrabenazine should not exceed 36 mg, and the maximum single dose of deutetrabenazine should not exceed 18 mg, with concurrent use of a strong CYP2D6 inhibitor. Risk D: Consider therapy modification

Dexlansoprazole: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Dexlansoprazole. Risk C: Monitor therapy

Dexmethylphenidate-Methylphenidate: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor therapy

Dextromethorphan: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors). This could result in serotonin syndrome. Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors) may increase the serum concentration of Dextromethorphan. Management: Consider alternatives to this drug combination. The dose of dextromethorphan/bupropion product should not exceed 1 tablet once daily. Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity. Risk D: Consider therapy modification

DiazePAM: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of DiazePAM. Risk C: Monitor therapy

Digoxin: FLUoxetine may increase the serum concentration of Digoxin. Risk C: Monitor therapy

DOXOrubicin (Conventional): CYP2D6 Inhibitors (Strong) may increase the serum concentration of DOXOrubicin (Conventional). Risk X: Avoid combination

DULoxetine: May enhance the antiplatelet effect of Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors). DULoxetine may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors). This could result in serotonin syndrome. Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors) may increase the serum concentration of DULoxetine. Management: Monitor for increased duloxetine effects/toxicities and signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperthermia, tremor, mental status changes) when these agents are combined. In addition, monitor for signs and symptoms of bleeding. Risk C: Monitor therapy

Edoxaban: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased. Risk C: Monitor therapy

Eletriptan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor therapy

Eliglustat: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Eliglustat. Management: Eliglustat dose is 84 mg daily with CYP2D6 inhibitors. Use is contraindicated (COI) when also combined with strong CYP3A4 inhibitors. When also combined with a moderate CYP3A4 inhibitor, use is COI in CYP2D6 EMs or IMs and should be avoided in CYP2D6 PMs. Risk D: Consider therapy modification

Enoxaparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Enoxaparin. Management: Discontinue antiplatelet agents prior to initiating enoxaparin whenever possible. If concomitant administration is unavoidable, monitor closely for signs and symptoms of bleeding. Risk D: Consider therapy modification

Ergot Derivatives: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor therapy

Etravirine: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Etravirine. Risk C: Monitor therapy

Fenfluramine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Fenfluramine. Management: Limit fenfluramine dose to 20 mg/day without concurrent stiripentol or to 17 mg/day with concomitant stiripentol and clobazam when used with a strong CYP2D6 inhibitor. Risk D: Consider therapy modification

Fesoterodine: CYP2D6 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine. Risk C: Monitor therapy

Flecainide: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Flecainide. Risk C: Monitor therapy

Flibanserin: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Flibanserin. Risk C: Monitor therapy

FluPHENAZine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of FluPHENAZine. Risk C: Monitor therapy

Fosphenytoin-Phenytoin: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Fosphenytoin-Phenytoin. Risk C: Monitor therapy

Galantamine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Galantamine. Risk C: Monitor therapy

Gefitinib: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Gefitinib. Risk C: Monitor therapy

Gilteritinib: May diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Avoid use of this combination if possible. If the combination cannot be avoided, monitor closely for evidence of reduced response to the selective serotonin reuptake inhibitor. Risk D: Consider therapy modification

Haloperidol: QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of Haloperidol. Risk C: Monitor therapy

Haloperidol: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Haloperidol. Risk C: Monitor therapy

Heparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Heparin. Management: Decrease the dose of heparin or agents with antiplatelet properties if coadministration is required. Risk D: Consider therapy modification

Herbal Products with Anticoagulant/Antiplatelet Effects (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur. Risk C: Monitor therapy

Iboga: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Iboga. Risk C: Monitor therapy

Ibritumomab Tiuxetan: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding. Risk C: Monitor therapy

Ibrutinib: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Icosapent Ethyl: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Iloperidone: CYP2D6 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P88 may be increased. CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P95 may be decreased. CYP2D6 Inhibitors (Strong) may increase the serum concentration of Iloperidone. Management: Reduce iloperidone dose by half when administered with a strong CYP2D6 inhibitor and monitor for increased iloperidone toxicities, including QTc interval prolongation and arrhythmias. Risk D: Consider therapy modification

Indoramin: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Indoramin. Risk C: Monitor therapy

Inotersen: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Ioflupane I 123: Selective Serotonin Reuptake Inhibitors may diminish the diagnostic effect of Ioflupane I 123. Risk C: Monitor therapy

Lansoprazole: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Lansoprazole. Risk C: Monitor therapy

Lasmiditan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor therapy

Levomethadone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor therapy

Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Linezolid: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Risk X: Avoid combination

Lipid Emulsion (Fish Oil Based): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Lofexidine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Lofexidine. Risk C: Monitor therapy

Lomitapide: FLUoxetine may increase the serum concentration of Lomitapide. Management: Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half with concurrent fluoxetine; the lomitapide dose may then be increased to a max adult dose of 30 mg/day (patients on lomitapide 5 mg/day may continue that dose). Risk D: Consider therapy modification

Lorcaserin (Withdrawn From US Market): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor therapy

Maprotiline: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Maprotiline. Risk C: Monitor therapy

Mavacamten: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Mavacamten. Risk X: Avoid combination

Mequitazine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Mequitazine. Risk X: Avoid combination

Metaxalone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor therapy

Methadone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor therapy

Methylene Blue: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome. Risk X: Avoid combination

Metoclopramide: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Metoclopramide. Management: For gastroparesis: reduce metoclopramide dose to 5mg 4 times/day and limit to 20mg/day; nasal spray not recommended. For GERD: reduce metoclopramide dose to 5mg 4 times/day or to 10mg 3 times/day and limit to 30mg/day. Monitor for toxicity when combined. Risk D: Consider therapy modification

Metoprolol: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Metoprolol. Risk C: Monitor therapy

MetyroSINE: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Risk C: Monitor therapy

Mexiletine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Mexiletine. Risk C: Monitor therapy

Mivacurium: Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Mivacurium. Risk C: Monitor therapy

Monoamine Oxidase Inhibitors (Antidepressant): Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Monoamine Oxidase Inhibitors (Antidepressant). This could result in serotonin syndrome. Risk X: Avoid combination

Multivitamins/Fluoride (with ADE): May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Multivitamins/Minerals (with AE, No Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Nebivolol: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Nebivolol. Risk C: Monitor therapy

Nefazodone: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor therapy

Nicergoline: CYP2D6 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Nicergoline. Specifically, concentrations of the MMDL metabolite may be increased. CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Nicergoline. Specifically, concentrations of the MDL metabolite may be decreased. Risk C: Monitor therapy

NIFEdipine: FLUoxetine may increase the serum concentration of NIFEdipine. Risk C: Monitor therapy

NiMODipine: FLUoxetine may increase the serum concentration of NiMODipine. Risk C: Monitor therapy

Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective). Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Risk C: Monitor therapy

Nonsteroidal Anti-Inflammatory Agents (Nonselective): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider alternatives to NSAIDs. Monitor for evidence of bleeding and diminished antidepressant effects. It is unclear whether COX-2-selective NSAIDs reduce risk. Risk D: Consider therapy modification

Nonsteroidal Anti-Inflammatory Agents (Topical): May enhance the antiplatelet effect of Selective Serotonin Reuptake Inhibitors. Risk C: Monitor therapy

Obinutuzumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. Risk C: Monitor therapy

Oliceridine: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors). This could result in serotonin syndrome. Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors) may increase the serum concentration of Oliceridine. Management: Monitor for increased opioid effects (eg, respiratory depression, sedation) and for serotonin syndrome/serotonin toxicity when these agents are combined. Risk C: Monitor therapy

Olmutinib: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Olmutinib. Risk C: Monitor therapy

Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Omeprazole: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Omeprazole. Risk C: Monitor therapy

Ondansetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor therapy

Opioid Agonists: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor therapy

Opioid Agonists (metabolized by CYP3A4 and CYP2D6): May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors). This could result in serotonin syndrome. Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors) may diminish the therapeutic effect of Opioid Agonists (metabolized by CYP3A4 and CYP2D6). Management: Monitor for decreased therapeutic response (eg, analgesia) and opioid withdrawal when coadministered with SSRIs that strongly inhibit CYP2D6. Additionally, monitor for serotonin syndrome/serotonin toxicity if these drugs are combined. Risk C: Monitor therapy

Opioid Agonists (metabolized by CYP3A4): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor therapy

Oxitriptan: Serotonergic Agents (High Risk) may enhance the serotonergic effect of Oxitriptan. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor therapy

Ozanimod: May enhance the adverse/toxic effect of Serotonergic Agents (High Risk). Risk C: Monitor therapy

PARoxetine: FLUoxetine may enhance the antiplatelet effect of PARoxetine. FLUoxetine may enhance the serotonergic effect of PARoxetine. This could result in serotonin syndrome. FLUoxetine may increase the serum concentration of PARoxetine. PARoxetine may increase the serum concentration of FLUoxetine. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, mental status changes), bleeding, and increased SSRI toxicities when these agents are combined. Risk C: Monitor therapy

Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents. Risk C: Monitor therapy

Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Perhexiline: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Perhexiline. Risk C: Monitor therapy

Perphenazine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Perphenazine. Risk C: Monitor therapy

Pimozide: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Pimozide. Risk X: Avoid combination

Pitolisant: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Pitolisant. Management: Reduce the pitolisant dose by 50% if a strong CYP2D6 inhibitor is initiated. For patients receiving strong CYP2D6 inhibitors, initiate pitolisant at 8.9 mg once daily and increase after 7 days to a maximum of 17.8 mg once daily. Risk D: Consider therapy modification

Primaquine: CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of Primaquine. CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Primaquine. Risk C: Monitor therapy

Proguanil: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Proguanil. CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Proguanil. Risk C: Monitor therapy

Propafenone: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Propafenone. Risk C: Monitor therapy

Propranolol: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Propranolol. Risk C: Monitor therapy

Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor therapy

Ramosetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor therapy

Rasagiline: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Rasagiline. This could result in serotonin syndrome. Risk X: Avoid combination

RisperiDONE: CYP2D6 Inhibitors (Strong) may increase the serum concentration of RisperiDONE. Management: Careful monitoring for risperidone toxicities and possible dose adjustment are recommended when combined with strong CYP2D6 inhibitors. See full interaction monograph for details. Risk D: Consider therapy modification

Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban. Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor. Risk C: Monitor therapy

Safinamide: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Management: Use the lowest effective dose of SSRIs in patients treated with safinamide and monitor for signs and symptoms of serotonin syndrome/serotonin toxicity. Risk D: Consider therapy modification

Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result. Risk C: Monitor therapy

Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of other Selective Serotonin Reuptake Inhibitors. Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of other Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, mental status changes) when these agents are combined. In addition, monitor for signs and symptoms of bleeding. Risk C: Monitor therapy

Selegiline: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Selegiline. This could result in serotonin syndrome. Risk X: Avoid combination

Selumetinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Serotonergic Agents (High Risk, Miscellaneous): May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor therapy

Serotonergic Non-Opioid CNS Depressants: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Serotonergic Non-Opioid CNS Depressants. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor therapy

Serotonergic Opioids (High Risk): May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) if these agents are combined. Risk C: Monitor therapy

Serotonin 5-HT1D Receptor Agonists (Triptans): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor therapy

Serotonin/Norepinephrine Reuptake Inhibitors: Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Serotonin/Norepinephrine Reuptake Inhibitors. Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, mental status changes) when these agents are combined. In addition, monitor for signs and symptoms of bleeding. Risk C: Monitor therapy

Sertindole: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Sertindole. Management: Consider alternatives to this combination when possible. If combined, consider using lower doses of sertindole and monitor the ECG closely for evidence of QTc interval prolongation. Risk D: Consider therapy modification

St John's Wort: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. St John's Wort may decrease the serum concentration of Serotonergic Agents (High Risk). Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor therapy

Syrian Rue: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor therapy

Tamoxifen: CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, strong CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites. Management: Avoid concurrent use of strong CYP2D6 inhibitors with tamoxifen when possible, as the combination may be associated with a reduced clinical effectiveness of tamoxifen. Risk D: Consider therapy modification

Tamsulosin: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Tamsulosin. Risk C: Monitor therapy

Tetrabenazine: CYP2D6 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Tetrabenazine. Specifically, concentrations of the active alpha- and beta-dihydrotetrabenazine metabolites may be increased. Management: Limit the tetrabenazine dose to 50 mg per day (25 mg per single dose) in patients taking strong CYP2D6 inhibitors. Risk D: Consider therapy modification

Thiazide and Thiazide-Like Diuretics: Selective Serotonin Reuptake Inhibitors may enhance the hyponatremic effect of Thiazide and Thiazide-Like Diuretics. Risk C: Monitor therapy

Thioridazine: FLUoxetine may increase the serum concentration of Thioridazine. Risk X: Avoid combination

Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. Risk C: Monitor therapy

Thyroid Products: Selective Serotonin Reuptake Inhibitors may diminish the therapeutic effect of Thyroid Products. Thyroid product dose requirements may be increased. Risk C: Monitor therapy

Timolol (Ophthalmic): CYP2D6 Inhibitors (Strong) may increase the serum concentration of Timolol (Ophthalmic). Risk C: Monitor therapy

Timolol (Systemic): CYP2D6 Inhibitors (Strong) may increase the serum concentration of Timolol (Systemic). Risk C: Monitor therapy

Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Tolterodine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Tolterodine. Risk C: Monitor therapy

TraMADol: Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors) may enhance the adverse/toxic effect of TraMADol. Specifically, the risk for serotonin syndrome/serotonin toxicity and seizures may be increased. Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors) may diminish the therapeutic effect of TraMADol. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes), seizures, and decreased tramadol efficacy when these agents are combined. Risk C: Monitor therapy

Tricyclic Antidepressants: FLUoxetine may enhance the serotonergic effect of Tricyclic Antidepressants. FLUoxetine may increase the serum concentration of Tricyclic Antidepressants. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) and increased TCA concentrations/effects if these agents are combined. Risk D: Consider therapy modification

Urokinase: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. Risk X: Avoid combination

Valbenazine: CYP2D6 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Valbenazine. Management: Reduce valbenazine dose to 40 mg once daily when combined with a strong CYP2D6 inhibitor. Monitor for increased valbenazine effects/toxicities. Risk D: Consider therapy modification

Vasopressin: Drugs Suspected of Causing SIADH may enhance the therapeutic effect of Vasopressin. Specifically, the pressor and antidiuretic effects of vasopressin may be increased. Risk C: Monitor therapy

Vitamin E (Systemic): May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Vitamin K Antagonists (eg, warfarin): Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K Antagonists. Risk C: Monitor therapy

Voriconazole: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Voriconazole. Risk C: Monitor therapy

Vortioxetine: Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors) may enhance the antiplatelet effect of Vortioxetine. Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors) may enhance the serotonergic effect of Vortioxetine. This could result in serotonin syndrome. Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors) may increase the serum concentration of Vortioxetine. Management: Consider alternatives to this drug combination. If combined, reduce the vortioxetine dose by half and monitor for signs and symptoms of bleeding and serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, autonomic instability). Risk D: Consider therapy modification

Zanubrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Zuclopenthixol: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol. Risk C: Monitor therapy

Reproductive Considerations

Fluoxetine is approved for the treatment of unipolar major depressive disorder. If treatment for major depressive disorder is initiated for the first time in patients planning to become pregnant, agents other than fluoxetine are preferred (use of fluoxetine is not preferred for use during pregnancy) (Larsen 2015).

Fluoxetine is also used off label for the treatment of premenstrual dysphoric disorder. For patients attempting to conceive, symptom onset dosing may be beneficial to minimize potential fetal exposure (Ismaili 2016; Lanza di Scalea 2019).

Selective serotonin reuptake inhibitors (SSRIs) may be associated with male and female treatment-emergent sexual dysfunction (Coskuner 2018; WFSBP [Bauer 2013]). Decreased libido and anorgasmia have been reported in females; abnormal ejaculation, decreased libido, and impotence have been reported in males with fluoxetine use. This may also be a manifestation of the psychiatric disorder. The actual risk associated with fluoxetine is not known. SSRI-related sexual dysfunction may resolve with dose reduction or discontinuation of the SSRI; in some cases, sexual dysfunction may persist once therapy is discontinued (Coskuner 2018; Jing 2016; Waldinger 2015).

Fluoxetine is used off label for the treatment of premature ejaculation. Although data is limited, some studies have shown SSRIs may impair the motility of spermatozoa, therefore use of other treatments may be preferred in patients planning to father a child (Althof 2014; Siroosbakht 2019; Sylvester 2019).

Pregnancy Considerations

Fluoxetine and its metabolite cross the placenta. Fluoxetine is cleared slowly by the newborn (Larsen 2015).

As a class, selective serotonin reuptake inhibitors (SSRIs) have been evaluated extensively in pregnant patients. Studies focusing on newborn outcomes following first trimester exposure often have inconsistent results due to differences in study design and confounders such as maternal disease and social factors. An increased risk of adverse cardiovascular events following in utero exposure to fluoxetine has been observed in some studies; however, a causal relationship has not been established (Anderson 2020; Biffi 2020; Fitton 2020; Reefhuis 2015; Womersley 2017).

Adverse effects in the newborn following SSRI exposure late in the third trimester can include apnea, constant crying, cyanosis, feeding difficulty, hyperreflexia, hypo- or hypertonia, hypoglycemia, irritability, jitteriness, respiratory distress, seizures, temperature instability, tremor, and vomiting. Prolonged hospitalization, respiratory support, or tube feedings may be required. Symptoms may be due to the toxicity of the SSRIs or a discontinuation syndrome and may be consistent with serotonin syndrome associated with SSRI treatment. Persistent pulmonary hypertension of the newborn has been reported with SSRI exposure; although the absolute risk is small, monitoring of infants exposed to SSRIs late in pregnancy is recommended (Masarwa 2019; Ng 2019). The long-term effects of in utero SSRI exposure on infant neurodevelopment and behavior are not known (CANMAT [MacQueen 2016]).

Due to pregnancy-induced physiologic changes, some pharmacokinetic parameters of fluoxetine may be altered (Heikkinen 2003; Hostetter 2000; Kim 2006; Sit 2010). However, dose adjustments may only be needed if symptoms recur or worsen during pregnancy. Close clinical monitoring as pregnancy progresses and therapeutic drug monitoring to detect patterns of changing plasma concentrations is recommended to assist dose adjustment when needed. If dosing is increased during pregnancy, a gradual taper to the prepregnancy range should be done postpartum (Betcher 2020; Schoretsanitis 2020; Sit 2010).

If treatment for major depressive disorder is initiated for the first time during pregnancy, fluoxetine is not one of the preferred SSRIs (CANMAT [MacQueen 2016]; Larsen 2015; WFSBP [Bauer 2013]). If pregnancy occurs during fluoxetine therapy, a change in treatment is only recommended if it can be safely done in relation to maternal disease (Larsen 2015). Untreated or inadequately treated psychiatric illness may lead to poor adherence with prenatal care and adverse pregnancy outcomes. Therapy with antidepressants during pregnancy should be individualized; treatment with antidepressant medication is recommended for pregnant patients with severe major depressive disorder (ACOG 2008; CANMAT [MacQueen 2016]). Patients treated for major depression and who are euthymic prior to pregnancy are more likely to experience a relapse when medication is discontinued (68%) as compared to pregnant patients who continue taking antidepressant medications (26%) (Cohen 2006).

Data collection to monitor pregnancy and infant outcomes following exposure to antidepressant medications is ongoing. Patients exposed to antidepressants during pregnancy are encouraged to enroll in the National Pregnancy Registry for Antidepressants. Pregnant patients 18 to 45 years of age or their health care providers may contact the registry to enroll; enrollment should be done as early in pregnancy as possible (1-866-961-2388 or https://womensmentalhealth.org/research/pregnancyregistry/antidepressants/).

Breastfeeding Considerations

Fluoxetine and its active metabolite (norfluoxetine) are present in breast milk.

Information related to the presence of fluoxetine in breast milk is available from multiple studies. The relative infant dose (RID) of fluoxetine has been calculated in review articles to be <12% of the weight adjusted maternal dose (Berle 2011; Orsolini 2015); RIDs up to 20% have also been located (Pogliani 2019).

- In one review, the RID of fluoxetine was calculated using pooled data from 149 mother/infant pairs providing an estimated daily infant dose via breast milk of 0.14 mg/day. The maternal dose and actual breast milk concentrations for the calculation were not provided. Infant plasma concentrations were up to 80% of those in the maternal plasma (Berle 2011).

- A second review included information from 280 cases; maternal daily doses of fluoxetine were 10 to 80 mg/day. The highest breast milk concentrations of fluoxetine presented were 17 to 293 ng/mL following maternal doses of 20 to 40 mg/day from a study of 11 women 2 to 23 weeks postpartum, providing a RID of 6.5%; norfluoxetine was also present in breast milk. Fluoxetine and norfluoxetine were detected in the serum of some infants (Orsolini 2015).

- A study published since these reviews reports a fluoxetine RID of 20%, following a maternal dose of 20 mg/day taken by one woman throughout pregnancy and continuing postpartum; sampling occurred within 7 days after delivery (fluoxetine concentrations 323.3 ng/mL [breast milk]; 216.8 ng/mL [maternal serum]) (Pogliani 2019).

- Concentrations of norfluoxetine in breast milk should also be considered. In a study of 19 women (20 infants), maternal and infant serum samples were obtained 5 to 34 weeks after delivery following maternal use of fluoxetine 10 to 60 mg/day. Fluoxetine was present in 30% of infant serum samples (range: <1 to 84 ng/mL) and norfluoxetine was present in 85% (range: <1 to 265 ng/mL). Breast milk was sampled in 9 cases. Peak breast milk concentrations of fluoxetine and norfluoxetine occurred 8 hours after the maternal dose and correlated highly with infant serum concentrations for norfluoxetine. The highest milk concentration of fluoxetine in this study was 235 ng/mL and the same mother also had the highest norfluoxetine milk concentration (222 ng/mL). These concentrations were obtained following a maternal dose of 40 mg/day. Women with serum concentrations of fluoxetine plus norfluoxetine <150 ng/mL had infants with low (<5 ng/mL) to nondetectable serum concentrations (Hendrick 2001).

- Based on available data, infants exposed to fluoxetine via breast milk are more likely to have elevated plasma concentrations in comparison to those exposed to other selective serotonin reuptake inhibitors (SSRIs) (Weissman 2004).

- In general, breastfeeding is considered acceptable when the RID is <10% (Anderson 2016; Ito 2000); however, some sources note breastfeeding should only be considered if the RID is <5% for psychotropic agents (Larsen 2015). When an RID is >25%, breastfeeding should generally be avoided (Anderson 2016; Ito 2000).

Adverse events in the breastfeeding infant have been reported following maternal use of fluoxetine, including agitation, irritability, poor feeding, and poor weight gain; crying, sleep disturbance, vomiting, and watery stools have also been reported (Kristensen 1999; Lester 1993). Infants exposed to an SSRI via breast milk should be monitored for irritability and changes in sleep, feeding patterns, and behavior, as well as growth and development (ABM [Sriraman 2015]; Sachs 2013; Weissman 2004; WFSBP [Bauer 2013]).

Maternal use of an SSRI during pregnancy may cause delayed lactogenesis (Marshall 2010), however the underlying maternal illness may also influence this outcome (Grzeskowiak 2018). Untreated severe or chronic depression in the postpartum period also has negative effects on the mother and the infant (Slomian 2019).

According to the manufacturer, the decision to breastfeed during fluoxetine therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.

Psychotherapy or other nonmedication therapies are recommended for the initial treatment of mild depression in breastfeeding patients; antidepressant medication is recommended when psychotherapy is not an option or symptoms are moderate to severe. If a specific SSRI was used effectively during pregnancy, it can be continued while breastfeeding if no contraindications exist (ABM [Sriraman 2015]).

When first initiating an antidepressant in a breastfeeding patient, agents other than fluoxetine are preferred (ABM [Sriraman 2015]; CANMAT [MacQueen 2016]; Larsen 2015).

Monitoring Parameters

Serum sodium in at-risk populations (as clinically indicated); blood glucose (for diabetic patients); liver and renal function (baseline and as clinically indicated); ECG assessment and periodic monitoring in patients with risk factors for QT prolongation and ventricular arrhythmia; closely monitor patients for depression, clinical worsening, suicidality, or unusual changes in behavior (eg, anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, mania, social functioning), particularly during the initial 1 to 2 months of therapy or during periods of dosage adjustments (increases or decreases); signs/symptoms of serotonin syndrome, such as mental status changes (eg, agitation, hallucinations, delirium, coma), autonomic instability (eg, tachycardia, labile BP, diaphoresis), neuromuscular changes (eg, tremor, rigidity, myoclonus), GI symptoms (eg, nausea, vomiting, diarrhea), and/or seizures; akathisia; sleep status

Reference Range

Therapeutic levels have not been well established.

Therapeutic: Fluoxetine: 100 to 800 ng/mL (SI: 289 to 2,314 nmol/L); Norfluoxetine: 100 to 600 ng/mL (SI: 289 to 1,735 nmol/L)

Toxic: Fluoxetine plus norfluoxetine: >2,000 ng/mL

Mechanism of Action

Inhibits CNS neuron serotonin reuptake; minimal or no effect on reuptake of norepinephrine or dopamine; does not significantly bind to alpha-adrenergic, histamine, or cholinergic receptors

Pharmacokinetics

Onset of action:

Anxiety disorders (generalized anxiety, panic, obsessive-compulsive disorder, posttraumatic stress disorder): Initial effects may be observed within 2 weeks of treatment, with continued improvements through 4 to 6 weeks (Issari 2016; Varigonda 2016; WFSBP [Bandelow 2012]); some experts suggest up to 12 weeks of treatment may be necessary for response, particularly in patients with obsessive-compulsive disorder and posttraumatic stress disorder (BAP [Baldwin 2014]; Katzman 2014; WFSBP [Bandelow 2012]).

Body dysmorphic disorder: Initial effects may be observed within 2 weeks; some experts suggest up to 12 to 16 weeks of treatment may be necessary for response in some patients (Phillips 2008).

Depression: Initial effects may be observed within 1 to 2 weeks of treatment, with continued improvements through 4 to 6 weeks (Papakostas 2006; Posternak 2005; Szegedi 2009; Taylor 2006).

Premenstrual dysphoric disorder: Initial effects may be observed within the first few days of treatment, with response at the first menstrual cycle of treatment (ISPMD [Nevatte 2013]).

Absorption: Well absorbed; delayed 1 to 2 hours with weekly formulation

Distribution: Vd: 12 to 43 L/kg

Protein binding: 95% to albumin and alpha1 glycoprotein

Metabolism: Hepatic, via CYP2C19 and 2D6, to norfluoxetine (activity equal to fluoxetine)

Half-life elimination: Adults:

Parent drug: 1 to 3 days (acute), 4 to 6 days (chronic), 7.6 days (cirrhosis)

Metabolite (norfluoxetine): 9.3 days (range: 4 to 16 days), 12 days (cirrhosis)

Time to peak, serum: 6 to 8 hours

Excretion: Urine (10% as norfluoxetine, 2.5% to 5% as fluoxetine)

Note: Weekly formulation results in greater fluctuations between peak and trough concentrations of fluoxetine and norfluoxetine compared to once-daily dosing (24% daily/164% weekly; 17% daily/43% weekly, respectively). Trough concentrations are 76% lower for fluoxetine and 47% lower for norfluoxetine than the concentrations maintained by 20 mg once-daily dosing. Steady-state fluoxetine concentrations are ~50% lower following the once-weekly regimen compared to 20 mg once daily. Average steady-state concentrations of once-daily dosing were highest in children ages 6 to <13 (fluoxetine 171 ng/mL; norfluoxetine 195 ng/mL), followed by adolescents ages 13 to <18 (fluoxetine 86 ng/mL; norfluoxetine 113 ng/mL); concentrations were considered to be within the ranges reported in adults (fluoxetine 91 to 302 ng/mL; norfluoxetine 72 to 258 ng/mL).

Pharmacokinetics: Additional Considerations

Hepatic function impairment: The half-life for fluoxetine and norfluoxetine is prolonged. Elimination half-life increased from 2.2 days in controls to 6.6 days and clearance decreased by 50% following a single dose of fluoxetine in patients with stable alcoholic cirrhosis (Mullish 2014; Schenker 1988).

Pediatric: Average steady-state fluoxetine serum concentrations in children (n=10; 6 to <13 years of age) were 2-fold higher than in adolescents (n=11; 13 to <18 years of age); all patients received 20 mg/day; average steady-state norfluoxetine serum concentrations were 1.5-fold higher in the children compared with adolescents; differences in weight almost entirely explained the differences in serum concentrations.

Pricing: US

Capsule, delayed release (FLUoxetine HCl Oral)

90 mg (per each): $39.21

Capsules (FLUoxetine HCl Oral)

10 mg (per each): $0.07 - $2.60

20 mg (per each): $0.07 - $2.67

40 mg (per each): $0.91 - $5.34

Capsules (PROzac Oral)

10 mg (per each): $20.18

20 mg (per each): $20.75

40 mg (per each): $41.50

Solution (FLUoxetine HCl Oral)

20 mg/5 mL (per mL): $0.98

Tablets (FLUoxetine HCl (PMDD) Oral)

10 mg (per each): $16.25

20 mg (per each): $16.25

Tablets (FLUoxetine HCl Oral)

10 mg (per each): $2.87 - $4.20

20 mg (per each): $4.20 - $17.34

60 mg (per each): $10.44 - $12.19

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Brand Names: International
  • Actan (CL, PY);
  • Actisac (TH);
  • Adef-XL (LK);
  • Adep (PH);
  • Adepssir (PH);
  • Adofen (ES);
  • Alzac (EG);
  • Anextin (BH, QA);
  • Ansi (ID);
  • Ansilan (CO);
  • Antiprestin (ID);
  • Azur (IT);
  • Bellzac (IE);
  • Biozac (BG);
  • Captaton (AR);
  • Daforin (BR);
  • Dagrilan (GR);
  • Dawnex (LK, ZW);
  • Deprexin (BM, BS, BZ, GY, HU, JM, SR, TT);
  • Deprizac (PH);
  • Deproxin (TH);
  • Dominium (EC);
  • Drafzin (PH);
  • Elevamood (EG);
  • Elizac (ID);
  • Exostrept (GR);
  • Flocept (ET);
  • Flonital (GR);
  • Flotina (IT);
  • Floxet (HK, HU, UY);
  • Flozak (BH);
  • Fluctine (AT, CH);
  • Fludac (BF, BJ, CI, ET, GH, GM, GN, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM);
  • Fludec (LK);
  • Fluketin (SG);
  • Fluneurin (BH);
  • Flunil (IN);
  • Fluovex (MY);
  • Fluox (NZ);
  • Fluoxeren (IT);
  • Fluoxone (FI, SG);
  • Fluronin (TW);
  • Flush (BD);
  • Flustad (NL);
  • Flutin (AE, CO, KW, MY, QA, SA);
  • Flutine (IL, TH);
  • Flux (LV);
  • Fluxen (TW, UA);
  • Fluxetin (HK);
  • Fluxil (AE, CY, IQ, IR, JO, LY, MT, OM, SA, SG, SY, TR, YE);
  • Fluzac (BD, IE);
  • Fluzyn-20 (BH);
  • Fontex (BE, DK, FI, IS, NO, SE);
  • Fropine (KR);
  • Fuloren (KR);
  • Fuxetine (KR);
  • Gerozac (IE);
  • Huma-Fluoxetin (HU);
  • Lanclic (KR);
  • Linz (QA);
  • Lorien (ZA);
  • Lovan (AU);
  • Luramon (ES);
  • Magrilan (HK);
  • Margrilan (AE, CY, IQ, IR, JO, LY, OM, PH, SA, SG, SY, YE);
  • Modipran (BD);
  • Motivest (PH);
  • Neupax (EC, PE);
  • Nopres (ID);
  • Nuzak (ZA);
  • Nycoflox (EE);
  • Octozac (EG);
  • Olena (GB);
  • Oxactin (MT);
  • Oxedep (CN, ZW);
  • Oxetin (BD);
  • Oxetine (AE, JO, LB, SA);
  • Oxexin (DK);
  • Plazeron (MT);
  • Portal (HR, HU, UA);
  • Praxin (HU);
  • Prazac (KR);
  • Prizma (IL);
  • Prodep (IN, UA);
  • Prolert (LK);
  • Prozac (AE, AR, AU, BB, BE, BF, BJ, BR, CI, CL, CN, CR, CZ, DO, EG, ES, ET, FR, GB, GH, GM, GN, GT, HK, HN, HU, IE, IL, JO, KE, KR, LR, LU, MA, ML, MR, MT, MU, MW, NE, NG, NI, NL, NZ, PA, PE, PK, PT, QA, RO, RU, SA, SC, SD, SG, SK, SL, SN, SV, TH, TN, TR, TZ, UG, VE, VN, ZM);
  • Prozac 20 (KR, MY, PH, TW);
  • Prozac Dispersible (KR);
  • Prozac Weekly (BB, KR);
  • Prozet (AU);
  • Prozit (TR);
  • Qualisac (HK);
  • Reneuron (ES);
  • Salipax (BM, BS, BZ, GY, JM, MY, PL, QA, SR, TT);
  • Seromex (FI);
  • Seronil (FI);
  • Sinzac (TW);
  • Symbyax (MX);
  • U-Zet (TW);
  • Youke (CN);
  • Zactin (AU, SG);
  • Zatin (CR, DO, GT, HN, NI, PA, SV)


For country code abbreviations (show table)
  1. Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F. Serotonin syndrome: analysis of cases registered in the French pharmacovigilance database. J Clin Psychopharmacol. 2015;35(4):382-388. doi:10.1097/JCP.0000000000000344 [PubMed 26082973]
  2. 2019 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019;67(4):674-694. doi: 10.1111/jgs.15767. [PubMed 30693946]
  3. ACOG Committee on Practice Bulletins--Obstetrics. ACOG practice bulletin: clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol. 2008;111(4):1001‐1020. doi:10.1097/AOG.0b013e31816fd910 [PubMed 18378767]
  4. Agrawal R, Almoghrabi A, Attar BM, Gandhi S. Fluoxetine-induced Stevens-Johnson syndrome and liver injury. J Clin Pharm Ther. 2019;44(1):115-118. doi:10.1111/jcpt.12760 [PubMed 30296343]
  5. Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319. [PubMed 11487763]
  6. Ahmad S. Fluoxetine and glaucoma. DICP. 1991;25(4):436. doi:10.1177/106002809102500422 [PubMed 1926918]
  7. Althof SE, McMahon CG, Waldinger MD, et al. An update of the International Society of Sexual Medicine's guidelines for the diagnosis and treatment of premature ejaculation (PE). Sex Med. 2014;2(2):60-90. doi:10.1002/sm2.28 [PubMed 25356302]
  8. American Academy of Child and Adolescent Psychiatry (AACAP). Practice parameter for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 2012;51(1):98-113. doi:10.1016/j.jaac.2011.09.019 [PubMed 22176943]
  9. American Psychiatric Association (APA). Practice guideline for the treatment of patients with borderline personality disorder. American Psychiatric Association. Am J Psychiatry. 2001;158(suppl 10):1-52. [PubMed 11665545]
  10. American Psychiatric Association (APA). Practice guideline for the treatment of patients with panic disorder. 2nd ed. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/panicdisorder.pdf. Published January 2009. Accessed August 2, 2018.
  11. American Psychiatric Association (APA). Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf Published October 2010. Accessed June 25, 2020.
  12. American Psychological Association (APA). Clinical practice guideline for the treatment of depression across three age cohorts. https://www.apa.org/depression-guideline/guideline.pdf. Published February 16, 2019. Accessed April 21, 2021.
  13. Anderson KN, Lind JN, Simeone RM, et al. Maternal use of specific antidepressant medications during early pregnancy and the risk of selected birth defects. JAMA Psychiatry. 2020;77(12):1246-1255. doi:10.1001/jamapsychiatry.2020.2453 [PubMed 32777011]
  14. Anderson PO, Sauberan JB. Modeling drug passage into human milk. Clin Pharmacol Ther. 2016;100(1):42-52. [PubMed 27060684]
  15. Andrade C, Sandarsh S, Chethan KB, Nagesh KS. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry. 2010;71(12):1565-1575. doi:10.4088/JCP.09r05786blu [PubMed 21190637]
  16. Anglin R, Yuan Y, Moayyedi P, Tse F, Armstrong D, Leontiadis GI. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109(6):811-819. doi:10.1038/ajg.2014.82 [PubMed 24777151]
  17. APO-Fluoxetine capsules and oral solution [product monograph]. Toronto, Ontario, Canada: Apotex Inc; January 2022.
  18. Arnold LM, McElroy SL, Hudson JI, Welge JA, Bennett AJ, Keck PE. A placebo-controlled, randomized trial of fluoxetine in the treatment of binge-eating disorder. J Clin Psychiatry. 2002a;63(11):1028-1033. [PubMed 12444817]
  19. Arnold LM, Hess EV, Hudson JI, Welge JA, Berno SE, Keck PE Jr. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med. 2002b;112(3):191-197. [PubMed 11893345]
  20. Aronoff GR, Bergstrom RF, Pottratz ST, Sloan RS, Wolen RL, Lemberger L. Fluoxetine kinetics and protein binding in normal and impaired renal function. Clin Pharmacol Ther. 1984;36(1):138-144. doi:10.1038/clpt.1984.152 [PubMed 6610522]
  21. Auerbach AD, Vittinghoff E, Maselli J, Pekow PS, Young JQ, Lindenauer PK. Perioperative use of selective serotonin reuptake inhibitors and risks for adverse outcomes of surgery. JAMA Intern Med. 2013;173(12):1075-1081. doi:10.1001/jamainternmed.2013.714 [PubMed 23699725]
  22. Baldessarini RJ, Faedda GL, Offidani E, et al. Antidepressant-associated mood-switching and transition from unipolar major depression to bipolar disorder: a review. J Affect Disord. 2013;148(1):129-135. doi:10.1016/j.jad.2012.10.033 [PubMed 23219059]
  23. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28(5):403-439. doi:10.1177/0269881114525674 [PubMed 24713617]
  24. Bandelow B, Sher L, Bunevicius R, et al; WFSBP Task Force on Mental Disorders in Primary Care; WFSBP Task Force on Anxiety Disorders, OCD and PTSD. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract. 2012;16(2):77-84. doi:10.3109/13651501.2012.667114 [PubMed 22540422]
  25. Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ; WFSBP Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders – first revision. World J Biol Psychiatry. 2008;9(4):248-312. doi:10.1080/15622970802465807 [PubMed 18949648]
  26. Barbuti M, Pacchiarotti I, Vieta E, et al. Antidepressant-induced hypomania/mania in patients with major depression: Evidence from the BRIDGE-II-MIX study. J Affect Disord. 2017;219:187-192. doi:10.1016/j.jad.2017.05.035 [PubMed 28558366]
  27. Barterian JA, Sanchez JM, Magen J, Siroky AK, Mash BL, Carlson JS. An examination of fluoxetine for the treatment of selective mutism using a nonconcurrent multiple-baseline single-case design across 5 cases. J Psychiatr Pract. 2018;24(1):2-14. doi:10.1097/PRA.0000000000000284 [PubMed 29320378]
  28. Bartlett D. Drug-induced serotonin syndrome. Crit Care Nurse. 2017;37(1):49-54. doi:10.4037/ccn2017169 [PubMed 28148614]
  29. Based on expert opinion.
  30. Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Möller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry. 2013;14(5):334-385. [PubMed 23879318]
  31. Bauer M, Severus E, Köhler S, et al; WFSBP Task Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. Part 2: maintenance treatment of major depressive disorder-update 2015. World J Biol Psychiatry. 2015;16(2):76-95. doi:10.3109/15622975.2014.1001786 [PubMed 25677972]
  32. Bauer M, Whybrow PC, Anst J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. World J Biol Psychiatry. 2002;3(2):69-86. [PubMed 12479080]
  33. Beer K, Albertini J, Medenica M, Busbey S. Fluoxetine-induced hypersensitivity. Arch Dermatol. 1994;130(6):803-804. [PubMed 8002659]
  34. Bellón T. Mechanisms of severe cutaneous adverse reactions: recent advances. Drug Saf. 2019;42(8):973-992. doi:10.1007/s40264-019-00825-2 [PubMed 31020549]
  35. Benazzi F. Antidepressant-associated hypomania in outpatient depression: a 203-case study in private practice. J Affect Disord. 1997;46(1):73-77. doi:10.1016/s0165-0327(97)00082-7 [PubMed 9387089]
  36. Benedek DM, Friedman MJ, Zatzick D, Ursano RJ. Guideline watch (March 2009): Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/acutestressdisorderptsd-watch.pdf. Published March 2009. Accessed July 30, 2021.
  37. Berle JO, Spigset O. Antidepressant use during breastfeeding. Curr Womens Health Rev. 2011;7(1):28-34. [PubMed 22299006]
  38. Betcher HK, Wisner KL. Psychotropic treatment during pregnancy: research synthesis and clinical care principles. J Womens Health (Larchmt). 2020;29(3):310‐318. doi:10.1089/jwh.2019.7781 [PubMed 31800350]
  39. Biffi A, Cantarutti A, Rea F, Locatelli A, Zanini R, Corrao G. Use of antidepressants during pregnancy and neonatal outcomes: an umbrella review of meta-analyses of observational studies. J Psychiatr Res. 2020;124:99-108. doi:10.1016/j.jpsychires.2020.02.023 [PubMed 32135392]
  40. Bilen S, Saka M, Ak F, Oztekin N. Persistent dystonia induced by fluoxetine. Intern Med J. 2008;38(8):672-674. doi:10.1111/j.1445-5994.2008.01747.x [PubMed 18808563]
  41. Birmaher B, Axelson DA, Monk K, et al. Fluoxetine for the treatment of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2003;42(4):415-423. doi:10.1097/01.CHI.0000037049.04952.9F [PubMed 12649628]
  42. Bixby AL, VandenBerg A, Bostwick JR. Clinical management of bleeding risk with antidepressants. Ann Pharmacother. 2019;53(2):186-194. doi:10.1177/1060028018794005 [PubMed 30081645]
  43. Black B, Uhde TW. Treatment of elective mutism with fluoxetine: a double blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry. 1994;33(7):1000-1006. [PubMed 7961338]
  44. Blacksten JV, Birt JA. Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine. Ann Pharmacother. 1993;27(6):723-724. doi:10.1177/106002809302700609 [PubMed 8329791]
  45. Blumenfield M, Levy NB, Spinowitz B, et al. Fluoxetine in depressed patients on dialysis. Int J Psychiatry Med. 1997;27(1):71-80. doi:10.2190/WQ33-M54T-XN7L-V8MX [PubMed 9565715]
  46. Bobo WV, Shelton RC. Bipolar major depression in adults: Efficacy and adverse effects of antidepressants. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed January 13, 2022.
  47. Bost RO, Kemp PM. A possible association between fluoxetine use and suicide. J Anal Toxicol. 1992;16(2):142-145. doi:10.1093/jat/16.2.142 [PubMed 1501465]
  48. Bostankolu G, Ayhan Y, Cuhadaroglu F, Yazıcı MK. Serotonin syndrome with a combination of aripiprazole and fluoxetine: a case report. Ther Adv Psychopharmacol. 2015;5(2):138-140. doi:10.1177/2045125314561467 [PubMed 26240751]
  49. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120. doi:10.1056/NEJMra041867 [PubMed 15784664]
  50. Brunner E, Tohen M, Osuntokun O, Landry J, Thase ME. Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder. Neuropsychopharmacology. 2014;39(11):2549-2559. doi:10.1038/npp.2014.101 [PubMed 24801768]
  51. Bruun SB, Petersen I, Kristensen NR, Cronin-Fenton D, Pedersen AB. Selective serotonin reuptake inhibitor use in hip fracture patients: a Danish nationwide prevalence study. Acta Orthop. 2019;90(1):33-39. doi:10.1080/17453674.2018.1543842 [PubMed 30526179]
  52. Burke D, Fanker S. Fluoxetine and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). Aust N Z J Psychiatry. 1996;30(2):295-298. doi:10.3109/00048679609076109 [PubMed 8811276]
  53. Bushnell GA, Compton SN, Dusetzina SB, et al. Treating pediatric anxiety: initial use of SSRIs and other antianxiety prescription medications. J Clin Psychiatry. 2018;79(1):16m11415. doi:10.4088/JCP.16m11415 [PubMed 29099547]
  54. Cai Q, Benson MA, Talbot TJ, et al. Acute hepatitis due to fluoxetine therapy. Mayo Clin Proc. 1999;74(7):692-694. doi:10.4065/74.7.692 [PubMed 10405699]
  55. Capellà D, Bruguera M, Figueras A, Laporte J. Fluoxetine-induced hepatitis: why is postmarketing surveillance needed?. Eur J Clin Pharmacol. 1999;55(7):545-546. doi:10.1007/s002280050671 [PubMed 10501826]
  56. Carvalho AF, Sharma MS, Brunoni AR, Vieta E, Fava GA. The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature. Psychother Psychosom. 2016;85(5):270-288. doi:10.1159/000447034 [PubMed 27508501]
  57. Casper RF, Yonkers KA. Treatment of premenstrual syndrome and premenstrual dysphoric disorder. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 13, 2020.
  58. Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. MMWR Morb Mortal Wkly Rep. 1982;31(22):290-291. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm [PubMed 6810084]
  59. Çetin B, Ergelen M. A case of fluoxetine-induced lower extremity ecchymosis. Prim Care Companion CNS Disord. 2017;19(3):10.4088/PCC.16l02061. Published 2017 Jun 15. doi:10.4088/PCC.16l02061 [PubMed 28636812]
  60. Ceylan ME, Maner F. Long-term use of fluoxetine and multiple skeleton fractures. Eur J Clin Pharmacol. 2010;66(12):1279. doi:10.1007/s00228-010-0880-8 [PubMed 20703452]
  61. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al, “Selective Serotonin-Reuptake Inhibitors and Risk of Persistent Pulmonary Hypertension of the Newborn,” N Engl J Med, 2006, 354(6):579-87. [PubMed 16467545]
  62. Chan CT, Chang SS, Yeh EK, Jou LC. Upper gastrointestinal bleeding in an end-stage renal disease patient treated with fluoxetine. Gen Hosp Psychiatry. 2011;33(5):530.e1-530.e5303. doi:10.1016/j.genhosppsych.2011.03.012 [PubMed 21749836]
  63. Chen HY, Lin CL, Lai SW, Kao CH. Association of selective serotonin reuptake inhibitor use and acute angle-closure glaucoma. J Clin Psychiatry. 2016;77(6):e692-e696. doi:10.4088/JCP.15m10038 [PubMed 27135704]
  64. Cheung AH, Zuckerbrot RA, Jensen PS, Laraque D, Stein REK; GLAD-PC Steering Group. Guidelines for Adolescent Depression in Primary Care (GLAD-PC): Part II. Treatment and ongoing management. Pediatrics. 2018;141(3):e20174082. doi:10.1542/peds.2017-4082 [PubMed 29483201]
  65. Chou PH, Chu CS, Chen YH, et al. Antidepressants and risk of cataract development: A population-based, nested case-control study. J Affect Disord. 2017;215:237-244. doi:10.1016/j.jad.2017.03.044 [PubMed 28342338]
  66. Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA. 2006;295(5):499-507. doi:10.1001/jama.295.5.499 [PubMed 16449615]
  67. Connor KM, Sutherland SM, Tupler LA, Malik ML, Davidson JR. Fluoxetine in post-traumatic stress disorder. Randomised, double-blind study. Br J Psychiatry. 1999;175:17-22. doi:10.1192/bjp.175.1.17 [PubMed 10621763]
  68. Coskuner ER, Culha MG, Ozkan B, Kaleagasi EO. Post-SSRI sexual dysfunction: preclinical to clinical. Is it fact or fiction?. Sex Med Rev. 2018;6(2):217-223. doi:10.1016/j.sxmr.2017.11.004 [PubMed 29463440]
  69. Costagliola C, Mastropasqua L, Steardo L, Testa N. Fluoxetine oral administration increases intraocular pressure. Br J Ophthalmol. 1996;80(7):678. doi:10.1136/bjo.80.7.678 [PubMed 8795389]
  70. Costagliola C, Parmeggiani F, Semeraro F, Sebastiani A. Selective serotonin reuptake inhibitors: a review of its effects on intraocular pressure. Curr Neuropharmacol. 2008;6(4):293-310. doi:10.2174/157015908787386104 [PubMed 19587851]
  71. Couturier J, Isserlin L, Norris M, et al. Canadian practice guidelines for the treatment of children and adolescents with eating disorders. J Eat Disord. 2020;8:4. doi:10.1186/s40337-020-0277-8 [PubMed 32021688]
  72. Craske M, Bystritsky A. Generalized anxiety disorder in adults: management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 15, 2021.
  73. Csoka AB, Bahrick A, Mehtonen OP. Persistent sexual dysfunction after discontinuation of selective serotonin reuptake inhibitors. J Sex Med. 2008;5(1):227-233. doi:10.1111/j.1743-6109.2007.00630.x [PubMed 18173768]
  74. Csoka AB, Shipko S. Persistent sexual side effects after SSRI discontinuation. Psychother Psychosom. 2006;75(3):187-188. doi:10.1159/000091777 [PubMed 16636635]
  75. Dall M, Schaffalitzky de Muckadell OB, Lassen AT, Hansen JM, Hallas J. An association between selective serotonin reuptake inhibitor use and serious upper gastrointestinal bleeding. Clin Gastroenterol Hepatol. 2009;7(12):1314-1321. doi:10.1016/j.cgh.2009.08.019 [PubMed 19716436]
  76. Davidson JR, Foa EB, Huppert JD, et al. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch Gen Psychiatry. 2004;61(10):1005-1013. [PubMed 15466674]
  77. de Kerviler E, Trédaniel J, Revlon G, et al. Fluoxetin-induced pulmonary granulomatosis. Eur Respir J. 1996;9(3):615-617. doi:10.1183/09031936.96.09030615 [PubMed 8730028]
  78. De Picker L, Van Den Eede F, Dumont G, Moorkens G, Sabbe BG. Antidepressants and the risk of hyponatremia: a class-by-class review of literature. Psychosomatics. 2014;55(6):536-547. doi:10.1016/j.psym.2014.01.010 [PubMed 25262043]
  79. Depression in children and young people: identification and management. London: National Institute for Health and Care Excellence (UK); June 25, 2019. [PubMed 31577402]
  80. DeSilva KE, Le Flore DB, Marston BJ, et al, “Serotonin Syndrome in HIV-Infected Individuals Receiving Antiretroviral Therapy and Fluoxetine,” AIDS, 2001, 15(10):1281-5. [PubMed 11426073]
  81. Dobson ET, Strawn JR. Pharmacotherapy for pediatric generalized anxiety disorder: a systematic evaluation of efficacy, safety and tolerability. Paediatr Drugs. 2016;18(1):45-53. doi:10.1007/s40272-015-0153-1 [PubMed 26660158]
  82. Dopheide JA, "Recognizing and Treating Depression in Children and Adolescents," Am J Health Syst Pharm, 2006, 63(3):233-43. [PubMed 16434782]
  83. Douros A, Ades M, Renoux C. Risk of intracranial hemorrhage associated with the use of antidepressants inhibiting serotonin reuptake: a systematic review. CNS Drugs. 2018;32(4):321-334. doi:10.1007/s40263-018-0507-7 [PubMed 29536379]
  84. Dow SP, Sonies BC, Scheib D, et al, "Practical Guidelines for the Assessment and Treatment of Selective Mutism," J Am Acad Child Adolesc Psychiatry, 1995, 34(7):836-46. [PubMed 7649953]
  85. Dubovsky SL, Thomas M. Tardive dyskinesia associated with fluoxetine. Psychiatr Serv. 1996;47(9):991-993. doi:10.1176/ps.47.9.991 [PubMed 8875667]
  86. Dummit ES 3rd, Klein RG, Tancer NK, Asche B, Martin J. Fluoxetine treatment of children with selective mutism: an open trial. J Am Acad Child Adolesc Psychiatry. 1996;35(5):615-621. [PubMed 8935208]
  87. Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-642. doi:10.1093/qjmed/hcg109 [PubMed 12925718]
  88. Durmaz O, Çelik S. Vaginal bleeding associated with antidepressants. Int J Gynaecol Obstet. 2015;130(3):284. doi:10.1016/j.ijgo.2015.03.024 [PubMed 25983210]
  89. Erie JC, Brue SM, Chamberlain AM, Hodge DO. Selective serotonin reuptake inhibitor use and increased risk of cataract surgery: a population-based, case-control study. Am J Ophthalmol. 2014;158(1):192-197.e1. doi:10.1016/j.ajo.2014.03.006 [PubMed 24631758]
  90. Fairbanks JM, Pine DS, Tancer NK, et al. Open fluoxetine treatment of mixed anxiety disorders in children and adolescents. J Child Adolesc Psychopharmacol. 1997;7(1):17-29. doi:10.1089/cap.1997.7.17 [PubMed 9192539]
  91. Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom. 2015;84(2):72-81. doi:10.1159/000370338 [PubMed 25721705]
  92. Fava M, Amsterdam JD, Deltito JA, Salzman C, Schwaller M, Dunner DL. A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression. Ann Clin Psychiatry. 1998;10(4):145-150. [PubMed 9988054]
  93. Fava M. Prospective studies of adverse events related to antidepressant discontinuation. J Clin Psychiatry. 2006;67(suppl 4):14-21. [PubMed 16683858]
  94. Fenske JN, Schwenk TL. Obsessive compulsive disorder: diagnosis and management. Am Fam Physician. 2009;80(3):239-245. [PubMed 19621834]
  95. Fitton CA, Steiner MFC, Aucott L, et al. In utero exposure to antidepressant medication and neonatal and child outcomes: a systematic review. Acta Psychiatr Scand. 2020;141(1):21-33. doi:10.1111/acps.13120 [PubMed 31648376]
  96. Fitzcharles MA, Ste-Marie PA, Goldenberg DL, et al. Canadian guidelines for the diagnosis and management of fibromyalgia syndrome. http://rheum.ca/wp-content/uploads/2017/11/2012CanadianFMGuidelines_17August2012.pdf. Published August 2012. Accessed February 5, 2021.
  97. Flores G, Perez-Patrigeon S, Cobos-Ayala C, Vergara J. Severe symptomatic hyponatremia during citalopram therapy--a case report. BMC Nephrol. 2004;5:2. doi:10.1186/1471-2369-5-2 [PubMed 14728721]
  98. Fluoxetine delayed-release capsules [prescribing information]. Bachupally, India: Dr. Reddy's Laboratories Limited; June 2021.
  99. Fluoxetine oral solution [prescribing information]. Philadelphia, PA: Lannett Company Inc; April 2021.
  100. Fluoxetine tablets [prescribing information]. Hauppauge, NY: ScieGen Pharmaceuticals Inc; October 2021.
  101. Fluoxetine tablets [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals; February 2022.
  102. Fluoxetine tablets [prescribing information]. Bachupally, India: Dr. Reddy's Laboratories Limited; June 2021.
  103. Friedenberg FK, Rothstein KD. Hepatitis secondary to fluoxetine treatment. Am J Psychiatry. 1996;153(4):580. doi:10.1176/ajp.153.4.580a [PubMed 8599417]
  104. Friedman RA, Leon AC. Expanding the black box - depression, antidepressants, and the risk of suicide. N Engl J Med. 2007;356(23):2343-2346. doi:10.1056/NEJMp078015 [PubMed 17485726]
  105. Gable KN and Dopheide JA. Psychotropic medication use at a private eating disorders treatment facility: A retrospective chart review and descriptive data analysis. Curr Ther Res Clin Exp. 2005;66:572-588.
  106. Gandhi S, Shariff SZ, Al-Jaishi A, et al. Second-Generation Antidepressants and Hyponatremia Risk: A Population-Based Cohort Study of Older Adults. Am J Kidney Dis. 2017;69(1):87-96. doi:10.1053/j.ajkd.2016.08.020 [PubMed 27773479]
  107. Gill N, Bayes A, Parker G. A review of antidepressant-associated hypomania in those diagnosed with unipolar depression-risk factors, conceptual models, and management. Curr Psychiatry Rep. 2020;22(4):20. doi:10.1007/s11920-020-01143-6 [PubMed 32215771]
  108. Gleason MM, Egger HL, Emslie GJ, et al. Psychopharmacological treatment for very young children: Contexts and guidelines. J Am Acad Child Adolesc Psychiatry. 2007;46(12):1532-1572. [PubMed 18030077]
  109. Go FS, Malley EE, Birmaher B, Rosenberg DR. Manic behaviors associated with fluoxetine in three 12- to 18-year-olds with obsessive-compulsive disorder. J Child Adolesc Psychopharmacol. 1998;8(1):73-80. doi:10.1089/cap.1998.8.73 [PubMed 9639082]
  110. Goldenberg D, Mayskiy M, Mossey C, Ruthazer R, Schmid C. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum. 1996;39(11):1852-1859. [PubMed 8912507]
  111. Goldenberg DL. Treatment of fibromyalgia in adults not responsive to initial therapies. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed July 6, 2022.
  112. Gonzalez-Rothi RJ, Zander DS, Ros PR. Fluoxetine hydrochloride (Prozac)-induced pulmonary disease. Chest. 1995;107(6):1763-1765. doi:10.1378/chest.107.6.1763 [PubMed 7781383]
  113. Gregorian RS, Golden KA, Bahce A, Goodman C, Kwong WJ, Khan ZM. Antidepressant-induced sexual dysfunction. Ann Pharmacother. 2002;36(10):1577-1589. doi:10.1345/aph.1A195 [PubMed 12243609]
  114. Grunze H, Vieta E, Goodwin GM, et al; WFSBP Task Force on Treatment Guidelines for Bipolar Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry. 2010;11(2):81-109. doi:10.3109/15622970903555881 [PubMed 20148751]
  115. Grunze H, Vieta E, Goodwin GM, et al; Members of the WFSBP Task Force on Bipolar Affective Disorders working on this topic. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: Acute and long-term treatment of mixed states in bipolar disorder. World J Biol Psychiatry. 2018;19(1):2-58. doi:10.1080/15622975.2017.1384850 [PubMed 29098925]
  116. Grzeskowiak LE, Leggett C, Costi L, Roberts CT, Amir LH. Impact of serotonin reuptake inhibitor use on breast milk supply in mothers of preterm infants: a retrospective cohort study. Br J Clin Pharmacol. 2018;84(6):1373-1379. doi:10.1111/bcp.13575 [PubMed 29522259]
  117. Haddad PM. Antidepressant discontinuation syndromes. Drug Saf. 2001;24(3):183-197. [PubMed 11347722]
  118. Halperin D, Reber G. Influence of antidepressants on hemostasis. Dialogues Clin Neurosci. 2007;9(1):47-59. [PubMed 17506225]
  119. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry. 2006;63(3):332-339. doi:10.1001/archpsyc.63.3.332 [PubMed 16520440]
  120. Hargrave R, Martinez D, Bernstein AJ. Fluoxetine-induced seizures. Psychosomatics. 1992;33(2):236-239. doi:10.1016/s0033-3182(92)72008-8 [PubMed 1557494]
  121. Hathaway EE, Walkup JT, Strawn JR. Antidepressant Treatment Duration in Pediatric Depressive and Anxiety Disorders: How Long is Long Enough? Curr Probl Pediatr Adolesc Health Care. 2018;48(2):31-39. [PubMed 29337001]
  122. Hay P, Chinn D, Forbes D, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of eating disorders. Aust N Z J Psychiatry. 2014;48(11):977-1008. doi:10.1177/0004867414555814 [PubMed 25351912]
  123. Heikkinen T, Ekblad U, Palo P, Laine K. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin Pharmacol Ther. 2003;73(4):330‐337. doi:10.1016/s0009-9236(02)17634-x [PubMed 12709723]
  124. Heller HM, Ravelli ACJ, Bruning AHL, et al. Increased postpartum haemorrhage, the possible relation with serotonergic and other psychopharmacological drugs: a matched cohort study. BMC Pregnancy Childbirth. 2017;17(1):166. doi:10.1186/s12884-017-1334-4 [PubMed 28577352]
  125. Hendrick V, Stowe ZN, Altshuler LL, et al. Fluoxetine and norfluoxetine concentrations in nursing infants and breast milk. Biol Psychiatry. 2001;50(10):775-782. doi:10.1016/s0006-3223(01)01197-0 [PubMed 11720696]
  126. Hetrick SE, McKenzie JE, Cox GR, Simmons MB, Merry SN. Newer generation antidepressants for depressive disorders in children and adolescents. Cochrane Database Syst Rev. 2012;11:CD004851. doi:10.1002/14651858.CD004851.pub3 [PubMed 23152227]
  127. Higgins A, Nash M, Lynch AM. Antidepressant-associated sexual dysfunction: impact, effects, and treatment. Drug Healthc Patient Saf. 2010;2:141-150. doi:10.2147/DHPS.S7634 [PubMed 21701626]
  128. Hirsch M, Birnbaum RJ. Discontinuing antidepressant medications in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed June 28, 2021a.
  129. Hirsch M, Birnbaum RJ. Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed March 9, 2021b.
  130. Hirsch M, Birnbaum RJ. Switching antidepressant medications in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed March 9, 2021c.
  131. Holtkamp K, Konrad K, Kaiser N, et al. A retrospective study of SSRI treatment in adolescent anorexia nervosa: insufficient evidence for efficacy. J Psychiatr Res. 2005;39(3):303-310. doi:10.1016/j.jpsychires.2004.08.001 [PubMed 15725429]
  132. Hornberger LL, Lane MA; Committee on Adolescence. Identification and management of eating disorders in children and adolescents. Pediatrics. 2021;147(1):e2020040279. doi:10.1542/peds.2020-040279 [PubMed 33386343]
  133. Hostetter A, Stowe ZN, Strader JR Jr, McLaughlin E, Llewellyn A. Dose of selective serotonin uptake inhibitors across pregnancy: clinical implications. Depress Anxiety. 2000;11(2):51‐57. [PubMed 10812529]
  134. Ignaszewski MJ, Waslick B. Update on randomized placebo-controlled trials in the past decade for treatment of major depressive disorder in child and adolescent patients: a systematic review. J Child Adolesc Psychopharmacol. 2018;28(10):668-675. doi:10.1089/cap.2017.0174 [PubMed 30063169]
  135. "Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. Pediatrics. 1997;99(2):268-278. [PubMed 9024461]
  136. Ismaili E, Walsh S, O'Brien PMS, et al; Consensus Group of the International Society for Premenstrual Disorders. Fourth consensus of the International Society for Premenstrual Disorders (ISPMD): auditable standards for diagnosis and management of premenstrual disorder. Arch Womens Ment Health. 2016;19(6):953-958. doi:10.1007/s00737-016-0631-7 [PubMed 27378473]
  137. Issari Y, Jakubovski E, Bartley CA, Pittenger C, Bloch MH. Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis. J Clin Psychiatry. 2016;77(5):605-611. doi:10.4088/JCP.14r09758 [PubMed 27249090]
  138. Ito S. Drug therapy for breast-feeding women. N Engl J Med. 2000;343(2):118-126. [PubMed 10891521]
  139. Jacob S, Spinler SA. Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults. Ann Pharmacother. 2006;40(9):1618-1622. doi:10.1345/aph.1G293 [PubMed 16896026]
  140. Javed MA. Priapism associated with fluoxetine therapy: a case report. J Pak Med Assoc. 1996;46(2):45-46. [PubMed 8683851]
  141. Jeong BO, Kim SW, Kim SY, Kim JM, Shin IS, Yoon JS. Use of serotonergic antidepressants and bleeding risk in patients undergoing surgery. Psychosomatics. 2014;55(3):213-220. doi:10.1016/j.psym.2013.08.011 [PubMed 24314591]
  142. Jerome L. Hypomania with fluoxetine. J Am Acad Child Adolesc Psychiatry. 1991;30(5):850-851. [PubMed 1938809]
  143. Jha MK, Rush AJ, Trivedi MH. When discontinuing SSRI antidepressants is a challenge: management tips. Am J Psychiatry. 2018;175(12):1176-1184. doi:10.1176/appi.ajp.2018.18060692 [PubMed 30501420]
  144. Jing E, Straw-Wilson K. Sexual dysfunction in selective serotonin reuptake inhibitors (SSRIs) and potential solutions: A narrative literature review. Ment Health Clin. 2016;6(4):191-196. doi:10.9740/mhc.2016.07.191 [PubMed 29955469]
  145. Jonsson GW, Moosa MY, Jeenah FY. Toxic epidermal necrolysis and fluoxetine: a case report. J Clin Psychopharmacol. 2008;28(1):93-95. doi:10.1097/jcp.0b013e3181604015 [PubMed 18204349]
  146. Kaakeh Y, Stumpf JL. Treatment of selective mutism: focus on selective serotonin reuptake inhibitors. Pharmacotherapy. 2008;28(2):214-224. [PubMed 18225967]
  147. Kara H, Aydin S, Yücel M, Agargün MY, Odabaş O, Yilmaz Y. The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study. J Urol. 1996;156(5):1631-1632. [PubMed 8863556]
  148. Katzman MA, Bleau P, Blier P, et al; Canadian Anxiety Guidelines Initiative Group. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14(suppl 1):S1. doi:10.1186/1471-244X-14-S1-S1 [PubMed 25081580]
  149. Kaya T, Yücel M, Eraslan Ö, Cinemre H, Tamer A. Severe hyponatremia, epistaxis, and fluoxetine. J Ayub Med Coll Abbottabad. 2016;28(1):204-205. [PubMed 27323598]
  150. Kaye WH, Nagata T, Weltzin TE, et al. Double-blind placebo-controlled administration of fluoxetine in restricting- and restricting-purging-type anorexia nervosa. Biol Psychiatry. 2001;49(7):644-652. doi:10.1016/s0006-3223(00)01013-1 [PubMed 11297722]
  151. Kesavan S, Sobala GM. Serotonin syndrome with fluoxetine plus tramadol. J R Soc Med. 1999;92(9):474-475. doi:10.1177/014107689909200915 [PubMed 10645303]
  152. Khan A, Khan S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry. 2003;160(4):790-792. doi:10.1176/appi.ajp.160.4.790 [PubMed 12668373]
  153. Khanassov V, Hu J, Reeves D, van Marwijk H. Selective serotonin reuptake inhibitor and selective serotonin and norepinephrine reuptake inhibitor use and risk of fractures in adults: A systematic review and meta-analysis. Int J Geriatr Psychiatry. 2018;33(12):1688-1708. doi:10.1002/gps.4974 [PubMed 30247774]
  154. Khera M, Cunningham GR. Treatment of male sexual dysfunction. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 24, 2018.
  155. Kim J, Riggs KW, Misri S, et al. Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding. Br J Clin Pharmacol. 2006;61(2):155‐163. doi:10.1111/j.1365-2125.2005.02538.x [PubMed 16433870]
  156. Kim S, Ko YJ, Park K, Yang BR, Kim MS, Park BJ. Fluoxetine and risk of bleeding in patients aged 60 years and older using the Korea Adverse Event Reporting System Database: a case/noncase study. J Clin Psychopharmacol. 2019;39(4):362-366. doi:10.1097/JCP.0000000000001059 [PubMed 31206390]
  157. King RA, Segman RH, Anderson GM. Serotonin and suicidality: the impact of acute fluoxetine administration. I: Serotonin and suicide. Isr J Psychiatry Relat Sci. 1994;31(4):271-279. [PubMed 7875951]
  158. Kirkham J, Seitz D. Evidence of ocular side effects of SSRIs and new warnings. Evid Based Ment Health. 2017;20(1):27. doi:10.1136/eb-2016-102528 [PubMed 27993931]
  159. Kline MD. Fluoxetine and anorgasmia. Am J Psychiatry. 1989;146(6):804-805. doi:10.1176/ajp.146.6.804 [PubMed 2786344]
  160. Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB; American Psychiatric Association. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry. 2007;164(7)(suppl):S5-S53. [PubMed 17849776]
  161. Kotler LA, Devlin MJ, Davies M, et al. An open trial of fluoxetine for adolescents with bulimia nervosa. J Child Adolesc Psychopharmacol. 2003;13(3):329-335. [PubMed 14642021]
  162. Kotapati VP, Khan AM, Dar S, et al. The effectiveness of selective serotonin reuptake inhibitors for treatment of obsessive-compulsive disorder in adolescents and children: a systematic review and meta-analysis. Front Psychiatry. 2019;10:523. doi:10.3389/fpsyt.2019.00523 [PubMed 31447707]
  163. Kristensen JH, Ilett KF, Hackett LP, Yapp P, Paech M, Begg EJ. Distribution and excretion of fluoxetine and norfluoxetine in human milk. Br J Clin Pharmacol. 1999;48(4):521-527. doi:10.1046/j.1365-2125.1999.00040.x [PubMed 10583022]
  164. Kupka R. Rapid cycling bipolar disorder in adults: Treatment of major depression. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed July 26, 2021.
  165. Labos C, Dasgupta K, Nedjar H, Turecki G, Rahme E. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. CMAJ. 2011;183(16):1835-1843. doi:10.1503/cmaj.100912 [PubMed 21948719]
  166. Lake MB, Birmaher B, Wassick S, Mathos K, Yelovich AK. Bleeding and selective serotonin reuptake inhibitors in childhood and adolescence. J Child Adolesc Psychopharmacol. 2000;10(1):35-38. doi:10.1089/cap.2000.10.35 [PubMed 10755580]
  167. Lanza di Scalea T, Pearlstein T. Premenstrual dysphoric disorder. Med Clin North Am. 2019;103(4):613-628. doi:10.1016/j.mcna.2019.02.007 [PubMed 31078196]
  168. Larsen ER, Damkier P, Pedersen LH, et al. Use of psychotropic drugs during pregnancy and breast-feeding. Acta Psychiatr Scand Suppl. 2015;(445):1-28. [PubMed 26344706]
  169. Lemberger L, Bergstrom RF, Wolen RL, Farid NA, Enas GG, Aronoff GR. Fluoxetine: clinical pharmacology and physiologic disposition. J Clin Psychiatry. 1985;46(3, pt 2):14-19. [PubMed 3871765]
  170. Leombruni P, Amianto F, Delsedime N, Gramaglia C, Abbate-Daga G, Fassino S. Citalopram versus fluoxetine for the treatment of patients with bulimia nervosa: a single-blind randomized controlled trial. Adv Ther. 2006;23(3):481-494. [PubMed 16912031]
  171. Leombruni P, Pierò A, Lavagnino L, Brustolin A, Campisi S, Fassino S. A randomized, double-blind trial comparing sertraline and fluoxetine 6-month treatment in obese patients with binge eating disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(6):1599-1605. doi:10.1016/j.pnpbp.2008.06.005 [PubMed 18598735]
  172. Leon AC. The revised warning for antidepressants and suicidality: unveiling the black box of statistical analyses. Am J Psychiatry. 2007;164(12):1786-1789. doi:10.1176/appi.ajp.2007.07050775 [PubMed 18056231]
  173. Lester BM, Cucca J, Andreozzi L, Flanagan P, Oh W. Possible association between fluoxetine hydrochloride and colic in an infant. J Am Acad Child Adolesc Psychiatry. 1993;32(6):1253-1255. doi:10.1097/00004583-199311000-00020 [PubMed 8282672]
  174. Levine R, Kenin M, Hoffman JS, Day-Knepple E. Grand mal seizures associated with the use of fluoxetine. J Clin Psychopharmacol. 1994;14(2):145-146. doi:10.1097/00004714-199404000-00011 [PubMed 8195457]
  175. Levinson-Castiel R, Merlob P, Linder N, et al, "Neonatal Abstinence Syndrome After in utero Exposure to Selective Serotonin Reuptake Inhibitors in Term Infants," Arch Pediatr Adolesc Med, 2006, 160(2):173-6. [PubMed 16461873]
  176. Levy NB, Blumenfield M, Beasley CM Jr, et al. Fluoxetine in depressed patients with renal failure and in depressed patients with normal kidney function. Gen Hosp Psychiatry. 1996;18(1):8-13. doi:10.1016/0163-8343(95)00073-9 [PubMed 8666216]
  177. Lewis JD, Strom BL, Localio AR, et al. Moderate and high affinity serotonin reuptake inhibitors increase the risk of upper gastrointestinal toxicity. Pharmacoepidemiol Drug Saf. 2008;17(4):328-335. doi:10.1002/pds.1546 [PubMed 18188866]
  178. Liebowitz MR, Turner SM, Piacentini J, et al. Fluoxetine in children and adolescents with OCD: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2002;41(12):1431-1438. doi:10.1097/00004583-200212000-00014 [PubMed 12447029]
  179. Liu BA, Mittmann N, Knowles SR, Shear NH. Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports [published correction appears in Can Med Assoc J 1996 Oct 15;155(8):1043]. CMAJ. 1996;155(5):519-527. [PubMed 8804257]
  180. Lock J, La Via MC; American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI). Practice parameter for the assessment and treatment of children and adolescents with eating disorders. J Am Acad Child Adolesc Psychiatry. 2015;54(5):412-425. doi:10.1016/j.jaac.2015.01.018 [PubMed 25901778]
  181. Loke YK, Trivedi AN, Singh S. Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2008;27(1):31-40. doi:10.1111/j.1365-2036.2007.03541.x [PubMed 17919277]
  182. Macfarlane GJ, Kronisch C, Dean LE, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017;76(2):318-328. doi:10.1136/annrheumdis-2016-209724 [PubMed 27377815]
  183. MacQueen GM, Frey BN, Ismail Z, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 6. Special populations: youth, women, and the elderly. Can J Psychiatry. 2016;61(9):588‐603. doi:10.1177/0706743716659276 [PubMed 27486149]
  184. Mander A, McCausland M, Workman B, Flamer H, Christophidis N. Fluoxetine induced dyskinesia. Aust N Z J Psychiatry. 1994;28(2):328-330. doi:10.1080/00048679409075647 [PubMed 7993290]
  185. Mannesse CK, Jansen PA, Van Marum RJ, et al. Characteristics, prevalence, risk factors, and underlying mechanism of hyponatremia in elderly patients treated with antidepressants: a cross-sectional study. Maturitas. 2013;76(4):357-363. doi:10.1016/j.maturitas.2013.08.010 [PubMed 24094459]
  186. Marshall AM, Nommsen-Rivers LA, Hernandez LL, et al. Serotonin transport and metabolism in the mammary gland modulates secretory activation and involution. J Clin Endocrinol Metab. 2010;95(2):837-846. doi:10.1210/jc.2009-1575 [PubMed 19965920]
  187. Martenyi F, Brown EB, Zhang H, Koke SC, Prakash A. Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder. Br J Psychiatry. 2002b;181:315-320. doi:10.1192/bjp.181.4.315 [PubMed 12356658]
  188. Martenyi F, Brown EB, Zhang H, Prakash A, Koke SC. Fluoxetine versus placebo in posttraumatic stress disorder. J Clin Psychiatry. 2002a;63(3):199-206. doi:10.4088/jcp.v63n0305 [PubMed 11926718]
  189. Martin A, Young C, Leckman JF, Mukonoweshuro C, Rosenheck R, Leslie D. Age effects on antidepressant-induced manic conversion. Arch Pediatr Adolesc Med. 2004;158(8):773-780. doi:10.1001/archpedi.158.8.773 [PubMed 15289250]
  190. Masarwa R, Bar-Oz B, Gorelik E, Reif S, Perlman A, Matok I. Prenatal exposure to selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors and risk for persistent pulmonary hypertension of the newborn: a systematic review, meta-analysis, and network meta-analysis. Am J Obstet Gynecol. 2019;220(1):57.e1-57.e13. doi:10.1016/j.ajog.2018.08.030 [PubMed 30170040]
  191. Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. Medicine (Baltimore). 2000;79(4):201-209. doi:10.1097/00005792-200007000-00001 [PubMed 10941349]
  192. Mauri MC, Fiorentini A, Paletta S, Altamura AC. Pharmacokinetics of antidepressants in patients with hepatic impairment. Clin Pharmacokinet. 2014;53(12):1069-1081. doi:10.1007/s40262-014-0187-5 [PubMed 25248846]
  193. McPheeters ML, Warren Z, Sathe N, et al, "A Systematic Review of Medical Treatments for Children With Autism Spectrum Disorders," Pediatrics, 2011, 127(5):e1312-21. [PubMed 21464191]
  194. McVoy M, Findling RL, eds. Clinical Manual of Child and Adolescent Psychopharmacology. 3rd ed. Amer Psychiatric Pub; 2017.
  195. Michael A, Mayer C. Fluoxetine-induced anaesthesia of vagina and nipples. Br J Psychiatry. 2000;176:299. doi:10.1192/bjp.176.3.299-a [PubMed 10755087]
  196. Miller LG, Bowman RC, Mann D, Tripathy A. A case of fluoxetine-induced serum sickness. Am J Psychiatry. 1989;146(12):1616-1617. doi:10.1176/ajp.146.12.1616 [PubMed 2589557]
  197. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry. 2001;62 Suppl 3:10-21. [PubMed 11229449]
  198. Montejo-González AL, Llorca G, Izquierdo JA, et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther. 1997;23(3):176-194. doi:10.1080/00926239708403923 [PubMed 9292833]
  199. Movig KL, Janssen MW, de Waal Malefijt J, Kabel PJ, Leufkens HG, Egberts AC. Relationship of serotonergic antidepressants and need for blood transfusion in orthopedic surgical patients. Arch Intern MedMurray MJ, Hooberman D. Fluoxetine and prolonged erection. Am J Psychiatry. 1993;150(1):167-168. doi:10.1176/ajp.150.1.167b. 2003;163(19):2354-2358. doi:10.1001/archinte.163.19.2354 [PubMed 14581256]
  200. Mullen S. Major depressive disorder in children and adolescents. Ment Health Clin. 2018;8(6):275-283. doi:10.9740/mhc.2018.11.275 [PubMed 30397569]
  201. Mullish BH, Kabir MS, Thursz MR, Dhar A. Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation. Aliment Pharmacol Ther. 2014;40(8):880-892. doi:10.1111/apt.12925 [PubMed 25175904]
  202. Murray MJ, Hooberman D. Fluoxetine and prolonged erection. Am J Psychiatry. 1993;150(1):167-168. doi:10.1176/ajp.150.1.167b [PubMed 8417566]
  203. National Collaborating Centre for Mental Health (NCCMH). Depression: The Treatment and Management of Depression in Adults (Updated Edition). National Institute for Health & Clinical Excellence (NICE). 2010. [PubMed 22132433]
  204. National Institute for Health and Care Excellence (NICE). Depression in children and young people: identification and management. London: National Institute for Health and Care Excellence (NICE); 2019. [PubMed 31577402]
  205. Nelson JC and Devanand DP. A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. J Am Geriatr Soc. 2011;59(4):577-585. [PubMed 21453380]
  206. Nevatte T, O'Brien PM, Bäckström T, et al; Consensus Group of the International Society for Premenstrual Disorders. ISPMD consensus on the management of premenstrual disorders. Arch Womens Ment Health. 2013;16(4):279-291. doi:10.1007/s00737-013-0346-y [PubMed 23624686]
  207. Ng QX, Venkatanarayanan N, Ho CYX, Sim WS, Lim DY, Yeo WS. Selective serotonin reuptake inhibitors and persistent pulmonary hypertension of the newborn: an update meta-analysis. J Womens Health (Larchmt). 2019;28(3):331-338. doi:10.1089/jwh.2018.7319 [PubMed 30407100]
  208. Ogle NR, Akkerman SR. Guidance for the discontinuation or switching of antidepressant therapies in adults. J Pharm Pract. 2013;26(4):389-396. doi:10.1177/0897190012467210 [PubMed 23459282]
  209. Opatrny L, Delaney JA, Suissa S. Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look. Br J Clin Pharmacol. 2008;66(1):76-81. doi:10.1111/j.1365-2125.2008.03154.x [PubMed 18460039]
  210. Orsolini L, Bellantuono C. Serotonin reuptake inhibitors and breastfeeding: a systematic review. Hum Psychopharmacol. 2015;30(1):4-20. doi:10.1002/hup.2451 [PubMed 25572308]
  211. Ozturk S, Ozsenel EB, Kazancioglu R, Turkmen A. A case of fluoxetine-induced syndrome of inappropriate antidiuretic hormone secretion. Nat Clin Pract Nephrol. 2008;4(5):278-282. doi:10.1038/ncpneph0780 [PubMed 18317501]
  212. Pai VB, Kelly MW. Bruising associated with the use of fluoxetine. Ann Pharmacother. 1996;30(7-8):786-788. doi:10.1177/106002809603000716 [PubMed 8826562]
  213. Papakostas GI, Perlis RH, Scalia MJ, Petersen TJ, Fava M. A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. J Clin Psychopharmacol. 2006;26(1):56-60. doi:10.1097/01.jcp.0000195042.62724.76 [PubMed 16415707]
  214. Patel DD, Galarneau D. Serotonin syndrome with fluoxetine: two case reports. Ochsner J. 2016;16(4):554-557. [PubMed 27999518]
  215. Patel R, Reiss P, Shetty H, et al. Do antidepressants increase the risk of mania and bipolar disorder in people with depression? A retrospective electronic case register cohort study. BMJ Open. 2015;5(12):e008341. doi:10.1136/bmjopen-2015-008341 [PubMed 26667012]
  216. Pediatric OCD Treatment Study (POTS) Team. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA. 2004;292(16):1969-1976. doi:10.1001/jama.292.16.1969 [PubMed 15507582]
  217. Phillips KA, Albertini RS, Rasmussen SA. A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder. Arch Gen Psychiatry. 2002;59(4):381-388. [PubMed 11926939]
  218. Phillips KA. Body dysmorphic disorder: Treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 24, 2018.
  219. Phillips KA, Hollander E. Treating body dysmorphic disorder with medication: evidence, misconceptions, and a suggested approach. Body Image. 2008;5(1):13-27. doi:10.1016/j.bodyim.2007.12.003 [PubMed 18325859]
  220. Pogliani L, Baldelli S, Cattaneo D, et al. Selective serotonin reuptake inhibitors' passage into human milk of lactating women. J Matern Fetal Neonatal Med. 2019;32(18):3020-3025. doi:10.1080/14767058.2018.1455180 [PubMed 29557689]
  221. Posternak MA, Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. J Clin Psychiatry. 2005;66(2):148-158. doi:10.4088/jcp.v66n0201 [PubMed 15704999]
  222. Practice parameter for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 2012;51(1):98-113. doi:10.1016/j.jaac.2011.09.019 [PubMed 22176943]
  223. Preeti S, Jayaram SD, Chittaranjan A. Sexual dysfunction in patients with antidepressant-treated anxiety or depressive disorders: a pragmatic multivariable longitudinal study. East Asian Arch Psychiatry. 2018;28(1):9-16. [PubMed 29588433]
  224. Prozac (fluoxetine) [prescribing information]. Indianapolis, IN: Lilly USA LLC; December 2021.
  225. Prozac (fluoxetine) [product monograph]. Toronto, Ontario, Canada: Eli Lilly Canada Inc; July 2021.
  226. Rabenda V, Nicolet D, Beaudart C, Bruyère O, Reginster JY. Relationship between use of antidepressants and risk of fractures: a meta-analysis. Osteoporos Int. 2013;24(1):121-137. doi:10.1007/s00198-012-2015-9 [PubMed 22638709]
  227. Reefhuis J, Devine O, Friedman JM, Louik C, Honein MA; National Birth Defects Prevention Study. Specific SSRIs and birth defects: Bayesian analysis to interpret new data in the context of previous reports. BMJ. 2015;351:h3190. doi:10.1136/bmj.h3190 [PubMed 26156519]
  228. Reeves RR, Ladner ME. Antidepressant-induced suicidality: an update. CNS Neurosci Ther. 2010;16(4):227-234. doi:10.1111/j.1755-5949.2010.00160.x [PubMed 20553304]
  229. Refer to manufacturer's labeling.
  230. Renoir T. Selective serotonin reuptake inhibitor antidepressant treatment discontinuation syndrome: a review of the clinical evidence and the possible mechanisms involved. Front Pharmacol. 2013;4:45. doi:10.3389/fphar.2013.00045 [PubMed 23596418]
  231. Richards JB, Papaioannou A, Adachi JD, et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med. 2007;167(2):188-194. doi:10.1001/archinte.167.2.188 [PubMed 17242321]
  232. Rizzoli R, Cooper C, Reginster JY, et al. Antidepressant medications and osteoporosis. Bone. 2012;51(3):606-613. doi:10.1016/j.bone.2012.05.018 [PubMed 22659406]
  233. Romano S, Goodman W, Tamura R, Gonzales J. Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo. J Clin Psychopharmacol. 2001;21(1):46-52. [PubMed 11199947]
  234. Rosen DS, American Academy of Pediatrics Committee on Adolescence. Identification and management of eating disorders in children and adolescents. Pediatrics. 2010;126(6):1240-1253. [PubMed 21115584]
  235. Rosenberg DR, Johnson K, Sahl R. Evolving mania in an adolescent treated with low-dose fluoxetine. J Child Adolesc Psychopharmacol. 1992;2(4):299-306. doi:10.1089/cap.1992.2.299 [PubMed 19630612]
  236. Rothschild AJ, Williamson DJ, Tohen MF, et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J Clin Psychopharmacol. 2004;24(4):365-373. [PubMed 15232326]
  237. Sachs HC, Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. Pediatrics. 2013;132(3):e796-809. [PubMed 23979084]
  238. Safer DJ, Zito JM. Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: children versus adolescents. J Child Adolesc Psychopharmacol. 2006;16(1-2):159-169. doi:10.1089/cap.2006.16.159 [PubMed 16553536]
  239. Samuel NG, Seifert CF. Risk of bleeding in patients on full-dose enoxaparin with venous thromboembolism and selective serotonin reuptake inhibitors. Ann Pharmacother. 2017;51(3):226-231. doi:10.1177/1060028016677309 [PubMed 27834194]
  240. Sarafem (fluoxetine) [prescribing information]. Madison, NJ: Allergan USA Inc; September 2021.
  241. Sarafem Pulvules (fluoxetine) [prescribing information]. Rockaway, NJ: Eli Lilly and Company; August 9, 2006.
  242. Schatzberg AF, Blier P, Delgado PL, et al. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. J Clin Psychiatry. 2006;67(Suppl 4):27-30. [PubMed 16683860]
  243. Schenker S, Bergstrom RF, Wolen RL, Lemberger L. Fluoxetine disposition and elimination in cirrhosis. Clin Pharmacol Ther. 1988;44(3):353-359. doi:10.1038/clpt.1988.161 [PubMed 3262026]
  244. Schoretsanitis G, Spigset O, Stingl JC, Deligiannidis KM, Paulzen M, Westin AA. The impact of pregnancy on the pharmacokinetics of antidepressants: a systematic critical review and meta-analysis. Expert Opin Drug Metab Toxicol. 2020;16(5):431‐440. doi:10.1080/17425255.2020.1750598 [PubMed 32238008]
  245. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol. 2009;29(3):259-266. doi:10.1097/JCP.0b013e3181a5233f [PubMed 19440080]
  246. Settle EC Jr, Settle GP. A case of mania associated with fluoxetine. Am J Psychiatry. 1984;141(2):280-281. doi:10.1176/ajp.141.2.280 [PubMed 6362443]
  247. Shakoor M, Ayub S, Ahad A, Ayub Z. Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor. Am J Case Rep. 2014;15:562-564. doi:10.12659/AJCR.892264 [PubMed 25540831]
  248. Shelton RC. Steps following attainment of remission: discontinuation of antidepressant therapy. Prim Care Companion J Clin Psychiatry. 2001;3(4):168-174. [PubMed 15014601]
  249. Shindel AW, Althof SE, Carrier S, et al. Disorders of ejaculation: an AUA/SMSNA guideline. J Urol. 2022;207(3):504-512. doi:10.1097/JU.0000000000002392 [PubMed 34961344]
  250. Simpson HB. Pharmacotherapy for obsessive-compulsive disorder in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 3, 2018.
  251. Siroosbakht S, Rezakhaniha S, Rezakhaniha B. Which of available selective serotonin reuptake inhibitors (SSRIs) is more effective in treatment of premature ejaculation? A randomized clinical trial. Int Braz J Urol. 2019;45(6):1209‐1215. doi:10.1590/S1677-5538.IBJU.2019.0121 [PubMed 31808410]
  252. Sit D, Perel JM, Luther JF, Wisniewski SR, Helsel JC, Wisner KL. Disposition of chiral and racemic fluoxetine and norfluoxetine across childbearing. J Clin Psychopharmacol. 2010;30(4):381‐386. doi:10.1097/JCP.0b013e3181e7be23 [PubMed 20631556]
  253. Slomian J, Honvo G, Emonts P, Reginster JY, Bruyère O. Consequences of maternal postpartum depression: a systematic review of maternal and infant outcomes. Womens Health (Lond). 2019;15:1745506519844044. doi:10.1177/1745506519844044 [PubMed 31035856]
  254. Sobieraj DM, Martinez BK, Hernandez AV, et al. Adverse effects of pharmacologic treatments of major depression in older adults. J Am Geriatr Soc. 2019;67(8):1571-1581. doi:10.1111/jgs.15966 [PubMed 31140587]
  255. Sriraman NK, Melvin K, Meltzer-Brody S. ABM clinical protocol #18: use of antidepressants in breastfeeding mothers. Breastfeed Med. 2015;10(6):290-299. [PubMed 26204124]
  256. Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord. 1998;51(3):215-235. doi:10.1016/s0165-0327(98)00221-3 [PubMed 10333979]
  257. Stein MB. Pharmacotherapy for social anxiety disorder in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 15, 2021.
  258. Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. Ann Pharmacother. 2008;42(9):1290-1297. [PubMed 18628446]
  259. Strawn JR, Welge JA, Wehry AM, Keeshin B, Rynn MA. Efficacy and tolerability of antidepressants in pediatric anxiety disorders: a systematic review and meta-analysis. Depress Anxiety. 2015;32(3):149-157. doi:10.1002/da.22329 [PubMed 25449861]
  260. Süleyman A, Kurt FS, Soyata AZ, Kaya I, Alyanak B. Henoch-Schönlein purpura during treatment with fluoxetine. J Child Adolesc Psychopharmacol. 2016;26(7):651. doi:10.1089/cap.2016.0045 [PubMed 27467827]
  261. Sun-Edelstein C, Tepper SJ, Shapiro RE. Drug-induced serotonin syndrome: a review. Expert Opin Drug Saf. 2008;7(5):587-596. doi:10.1517/14740338.7.5.587 [PubMed 18759711]
  262. Sylvester C, Menke M, Gopalan P. Selective serotonin reuptake inhibitors and fertility: considerations for couples trying to conceive. Harv Rev Psychiatry. 2019;27(2):108-118. doi:10.1097/HRP.0000000000000204 [PubMed 30676405]
  263. Sysko R, Devlin M. Binge eating disorder in adults: Overview of treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 3, 2018.
  264. Szegedi A, Jansen WT, van Willigenburg AP, van der Meulen E, Stassen HH, Thase ME. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry. 2009;70(3):344-353. doi:10.4088/jcp.07m03780 [PubMed 19254516]
  265. Taddio A, Ito S, and Koren G, "Excretion of Fluoxetine and its Metabolite, Norfluoxetine, in Human Breast Milk," J Clin Pharmacol, 1996, 36(1):42-7. [PubMed 8932542]
  266. Tan Pei Lin L, Kwek SK. Onset of psoriasis during therapy with fluoxetine. Gen Hosp Psychiatry. 2010;32(4):446.e9-446.e10. doi:10.1016/j.genhosppsych.2009.08.008 [PubMed 20633754]
  267. Targownik LE, Bolton JM, Metge CJ, Leung S, Sareen J. Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. Am J Gastroenterol. 2009;104(6):1475-1482. doi:10.1038/ajg.2009.128 [PubMed 19491861]
  268. Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Arch Gen Psychiatry. 2006;63(11):1217-23. doi:10.1001/archpsyc.63.11.1217 [PubMed 17088502]
  269. Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry. 1990;147(2):207-210. doi:10.1176/ajp.147.2.207 [PubMed 2301661]
  270. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression [published correction appears in Arch Gen Psychiatry. 2004;61(2):176]. Arch Gen Psychiatry. 2003;60(11):1079-1088. [PubMed 14609883]
  271. Tomlin AM, Reith DM, Woods DJ, et al. A pharmacoepidemiology database system for monitoring risk due to the use of medicines by New Zealand primary care patients. Drug Saf. 2017;40(12):1259-1277. doi:10.1007/s40264-017-0579-1 [PubMed 28766108]
  272. Tondo L, Vázquez G, Baldessarini RJ. Mania associated with antidepressant treatment: comprehensive meta-analytic review. Acta Psychiatr Scand. 2010;121(6):404-414. doi:10.1111/j.1600-0447.2009.01514.x [PubMed 19958306]
  273. Tuman TC, Tuman B, Polat M, Çakır U. Urticaria and Angioedema Associated with Fluoxetine. Clin Psychopharmacol Neurosci. 2017;15(4):418-419. doi:10.9758/cpn.2017.15.4.418 [PubMed 29073757]
  274. Türkoğlu S, Türkoğlu G. Vaginal bleeding and hemorrhagic prepatellar bursitis in a preadolescent girl, possibly related to fluoxetine. J Child Adolesc Psychopharmacol. 2015;25(2):186-187. doi:10.1089/cap.2014.0124 [PubMed 25749013]
  275. Ursano RJ, Bell C, Eth S, et al; Work Group on ASD and PTSD; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. Am J Psychiatry. 2004;161(11)(suppl):S3-S31. [PubMed 15617511]
  276. US Department of Veterans Affairs/Department of Defense (VA/DoD). VA/DoD clinical practice guideline for the management of posttraumatic stress disorder and acute stress disorder. Version 3.0. https://www.healthquality.va.gov/guidelines/MH/ptsd/VADoDPTSDCPGFinal012418.pdf. Published 2017. Accessed July 20, 2021.
  277. van Geffen EC, Hugtenburg JG, Heerdink ER, van Hulten RP, Egberts AC. Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation. Eur J Clin Pharmacol. 2005;61(4):303-307. doi:10.1007/s00228-005-0921-x [PubMed 15906018]
  278. Varigonda AL, Jakubovski E, Bloch MH. Systematic review and meta-analysis: early treatment responses of selective serotonin reuptake inhibitors and clomipramine in pediatric obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 2016;55(10):851-859.e2. doi:10.1016/j.jaac.2016.07.768 [PubMed 27663940]
  279. Vestergaard P, Rejnmark L, Mosekilde L. Selective serotonin reuptake inhibitors and other antidepressants and risk of fracture. Calcif Tissue Int. 2008;82(2):92-101. doi:10.1007/s00223-007-9099-9 [PubMed 18219438]
  280. Vignesh P, Kishore J, Kumar A, et al. A young child with eosinophilia, rash, and multisystem illness: drug rash, eosinophilia, and systemic symptoms syndrome after receipt of fluoxetine. Pediatr Dermatol. 2017;34(3):e120-e125. doi:10.1111/pde.13131 [PubMed 28523892]
  281. Wadhwa R, Kumar M, Talegaonkar S, Vohora D. Serotonin reuptake inhibitors and bone health: A review of clinical studies and plausible mechanisms. Osteoporos Sarcopenia. 2017;3(2):75-81. doi:10.1016/j.afos.2017.05.002 [PubMed 30775508]
  282. Waldinger MD. Psychiatric disorders and sexual dysfunction. Handb Clin Neurol. 2015;130:469-489. doi:10.1016/B978-0-444-63247-0.00027-4 [PubMed 26003261]
  283. Walsh BT, Kaplan AS, Attia E, et al. Fluoxetine after weight restoration in anorexia nervosa: a randomized controlled trial. JAMA. 2006;295(22):2605-2612. doi:10.1001/jama.295.22.2605 [PubMed 16772623]
  284. Walter HJ, Bukstein OG, Abright AR, et al. Clinical practice guideline for the assessment and treatment of children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2020;59(10):1107-1124. doi:10.1016/j.jaac.2020.05.005 [PubMed 32439401]
  285. Wang CY, Fu SH, Wang CL, Chen PJ, Wu FL, Hsiao FY. Serotonergic antidepressant use and the risk of fracture: a population-based nested case-control study. Osteoporos Int. 2016;27(1):57-63. doi:10.1007/s00198-015-3213-z [PubMed 26126579]
  286. Wang Z, Whiteside S, Sim L, et al. Anxiety in Children. Comparative Effectiveness Review No. 192. (Prepared by the Mayo Clinic Evidence-based Practice Center under Contract No. 290-2015-00013-I.) AHRQ Publication No. 17-EHC023-EF. Rockville, MD: Agency for Healthcare Research and Quality; August 2017. Erratum July 2018. doi:10.23970/AHRQEPCCER192
  287. Warden SJ, Fuchs RK. Do selective serotonin reuptake inhibitors (SSRIs) cause fractures? Curr Osteoporos Rep. 2016;14(5):211-218. doi:10.1007/s11914-016-0322-3 [PubMed 27495351]
  288. Warner, CH, Bobo W, Warner C, et al. Antidepressant discontinuation syndrome. Am Fam Physician. 2006;74:449-456. [PubMed 16913164]
  289. Wee TC. Gastrointestinal hemorrhage related to fluoxetine in a patient with stroke. Am J Phys Med Rehabil. 2017;96(11):e201-e203. doi:10.1097/PHM.0000000000000708 [PubMed 28141599]
  290. Weintrob N, Cohen D, Klipper-Aurbach Y, et al, “Decreased Growth During Therapy With Selective Serotonin Reuptake Inhibitors,” Arch Pediatr Adolesc Med, 2002, 156(7):696-701. [PubMed 12090838]
  291. Weissman AM, Levy BT, Hartz AJ, et al. Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. Am J Psychiatry. 2004;161(6):1066-1078. doi:10.1176/appi.ajp.161.6.1066 [PubMed 15169695]
  292. Westin AA, Brekke M, Molden E, Skogvoll E, Spigset O. Selective serotonin reuptake inhibitors and venlafaxine in pregnancy: Changes in drug disposition. PLoS One. 2017;12(7):e0181082. doi:10.1371/journal.pone.0181082 [PubMed 28708853]
  293. Williams AJ, Lai Z, Knight S, Kamali M, Assari S, McInnis MG. Risk factors associated with antidepressant exposure and history of antidepressant-induced mania in bipolar disorder. J Clin Psychiatry. 2018;79(3):17m11765. doi:10.4088/JCP.17m11765 [PubMed 29873955]
  294. Womersley K, Ripullone K, Agius M. What are the risks associated with different selective serotonin re-uptake inhibitors (SSRIs) to treat depression and anxiety in pregnancy? An evaluation of current evidence. Psychiatr Danub. 2017;29(suppl 3):629-644. [PubMed 28953843]
  295. Yektaş Ç, Tufan AE. Increased trichotillomania symptoms in a child with fluoxetine treatment. Clin Neuropharmacol. 2017;40(2):95-96. doi:10.1097/WNF.0000000000000205 [PubMed 28118168]
  296. Yucel A, Yucel N, Ozcan H, Gulec M, Aydin A. Fluoxetine associated with thrombocytopenia and treatment with reboxetine: 3 cases. J Clin Psychopharmacol. 2015;35(3):354-355. doi:10.1097/JCP.0000000000000301 [PubMed 25822478]
Topic 8465 Version 648.0